Utah State University

DigitalCommons@USU
All Graduate Theses and Dissertations

Graduate Studies

5-2016

Synthesis, Structure-Activity Relationship Study, and Mode of
Action Study of 1,4-Naphthoquinone Based Anticancer and
Antimicrobial Agents
Jaya P. Shrestha
Utah State University

Follow this and additional works at: https://digitalcommons.usu.edu/etd
Part of the Chemistry Commons

Recommended Citation
Shrestha, Jaya P., "Synthesis, Structure-Activity Relationship Study, and Mode of Action Study of
1,4-Naphthoquinone Based Anticancer and Antimicrobial Agents" (2016). All Graduate Theses and
Dissertations. 4925.
https://digitalcommons.usu.edu/etd/4925

This Dissertation is brought to you for free and open
access by the Graduate Studies at
DigitalCommons@USU. It has been accepted for
inclusion in All Graduate Theses and Dissertations by an
authorized administrator of DigitalCommons@USU. For
more information, please contact
digitalcommons@usu.edu.

SYNTHESIS, STRUCTURE-ACTIVITY RELATIONSHIP STUDY, AND MODE
OF ACTION STUDY OF 1,4-NAPHTHOQUINONE BASED
ANTICANCER AND ANTIMICROBIAL AGENTS
by
Jaya P. Shrestha
A dissertation submitted in partial fulfillment
of the requirements for the degree
of
DOCTOR OF PHILOSOPHY
in
Chemistry
Approved:
________________________
Cheng-Wei Tom Chang, Ph.D.
Major Professor

____________________
Alvan C. Hengge, Ph.D.
Committee Member

______________________
Bradley S. Davidson, Ph.D.
Committee Member

____________________
Robert S. Brown, Ph.D.
Committee Member

______________________
Jon Y. Takemoto, Ph.D.
Committee Member

____________________
Mark R. McLellan
Vice President for Research and
Dean of the School of Graduate Studies

UTAH STATE UNIVERSITY
Logan, Utah
2016

ii

Copyright © Jaya P. Shrestha 2016
All Rights Reserved

iii

ABSTRACT
Synthesis, Structure-Activity Relationship Study, and Mode of Action Study of
1,4-Naphthoquinone Based Anticancer and Antimicrobial Agents
by
Jaya P. Shrestha, Doctor of Philosophy
Utah State University, 2016

Major Professor: Cheng-Wei Tom Chang
Department: Chemistry and Biochemistry
Synthesizing bioactive small molecules by structural modification of
1,4-naphthoquinone was the primary goal of this research. Several bioactive
compounds with anticancer, antifungal, and antibacterial activities were
synthesized. All the synthetic protocols were optimized in such ways that do
not require cumbersome purification.
First, a new protocol for the synthesis of NQM111 was developed.
NQM111 is a highly potent anticancer agent developed in our laboratory, but
the old protocol does not provide enough quantity for in vivo study. Therefore,
a new safe and improved method was developed which provides enough
quantity for in vivo study.
The second project involves the synthesis of 1,4-naphthoquinone
conjugated with an aromatic group. These compounds are a highly potent
anticancer agent with ~8-fold selectivity towards cancer cell lines than the
non-cancer cell line. A mode of action study of this compound was identified,
and it was observed that these compounds generate reactive oxygen species,
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which triggers apoptosis.
The final project involves the synthesis of 1,4-naphthoquinone based
antifungal, and antibacterial compounds. These compounds are multi-cationic
in nature with a hydrophobic tail. Six different analogs with varying
hydrophobic tails were synthesized and tested for their antibacterial and
antifungal activity. These compounds showed excellent activity against wide
range of fungi including resistant strains.
(246 Pages)
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PUBLIC ABSTRACT

Synthesis, Structure-Activity Relationship Study, and Mode of Action Study of
1,4-Naphthoquinone Based Anticancer and Antimicrobial Agents
by
Jaya P. Shrestha, Doctor of Philosophy
Utah State University, 2016

The first three projects involve the synthesis and the mode of action
study of 1,4-naphthoquinone based anticancer agents. These anticancer
agents are highly potent against a wide range of cancer cell lines. These
compounds showed ~8-fold selectivity towards the lung cancer cell line than
the normal cell line. We also studied the mode of action and observed that
generation of reactive oxygen species is the primary mode of action.
The final project involves the synthesis of multi-cationic antimicrobial
agents. These compounds are active against both bacteria and fungi. These
compounds are very easy to synthesize and can be scaled up if large
quantities are needed.

vi

ACKNOWLEDGMENTS

First, I would like to express my sincere gratitude to my advisor, Dr.
Cheng-Wei Tom Chang, for his dedicated and seemingly tireless efforts in
molding me into a research scientist. The enthusiasm he has for his research
was contagious, and it was a driving force for me during the entire period of
my Ph.D. Humble by nature, he was a very approachable and I never had to
hesitate to ask him even a simple question. I could not have imagined having
a better advisor and mentor for my Ph.D. study.
I would like to thank all the members of my supervisory committee: Dr.
Alvan C. Hengge, Dr. Bradley S. Davidson, Dr. Jon Y. Takemoto and Dr.
Robert Brown. I would also like to thank my former committee member, Dr.
Liohai Chen. I appreciate all their support, encouragements, and insightful
comments, which greatly helped me through my development as a research
scientist and widen my research from various perspective.
I would like to thank all my former and current lab members: Dr. Marina
Y. Fosso, Dr. Qian Zhang, Vincent Nziko, Madher Alfindee, Yagya P. Subedi;
and also undergraduate researchers: Coleman Baker, Jeremiah Bearss,
Brock Davis, and Joseph Leishman.
I am also grateful to Dr. Sanjib Shrestha for gel electrophoresis
training, and Dr. Yukie Kawasaki for carrying out an antifungal study for the
compounds I have synthesized. I would also like to thank Dr. Jianhua Gong
for teaching me cell culture techniques and Claire Hanson at the Science
Writing Center (SWC) in USU for correcting grammatical errors in my

vii

dissertation.
Finally, I would like to thank the Department of Chemistry and
Biochemistry, and Utah State University for offering me the opportunity to
pursue my Ph.D.
Jaya P Shrestha, 2016

viii

CONTENTS
Page

ABSTRACT .................................................................................................... iii
PUBLIC ABSTRACT ....................................................................................... v
ACKNOWLEDGMENTS ................................................................................ vi
LIST OF TABLES ........................................................................................... x
LIST OF FIGURES ........................................................................................xii
LIST OF SCHEMES ..................................................................................... xvii
LIST OF ABBREVIATIONS ......................................................................... xviii
LIST OF SPECTRA .......................................................................................xxi
LIST OF CYCLIC VOLTAMMOGRAM ........................................................ xxvii
CHAPTER
1. GENERAL INTRODUCTION ................................................................ 1
2. SAFE AND EASY ROUTE FOR THE SYNTHESIS OF 1,3-1,2,3TRIAZOLIUM SALT AND INVESTIGATION OF ITS ANTICANCER
ACTIVITIES ........................................................................................ 42
3. SYNTHESIS AND ANTICANCER STRUCTURE ACTIVITY
RELATIONSHIP INVESTIGATION OF CATIONIC
ANTHRAQUINONE ANALOGS ......................................................... 56
4. A MODE OF ACTION STUDY OF CATIONIC ANTHRAQUINONE
ANALOGS: A NEW CLASS OF HIGHLY POTENT ANTICANCER
AGENTS ............................................................................................. 86
5. SYNTHESIS AND BIOORGANIC INVESTIGATION OF
QUINONE BASED MULTI-CATIONIC TRIAZOLIUM
AMPHIPHILES ................................................................................. 124
APPENDICES ............................................................................................ 143
APPENDIX A......................................................................................... 145

ix

APPENDIX B......................................................................................... 197
APPENDIX C ........................................................................................ 207
CURRICULUM VITAE ................................................................................ 215

x

LIST OF TABLES

Table

Page

2.1. GI50 values of NQM111 for different types of melanoma ....................... 49
2.2. GI50 values of NQM111 for different types of colon cancer ..................... 50
2.3. GI50 values of NQM111 for different types of non-small cell lung
cancers .................................................................................................. 50
2.4. GI50 values of NQM111 for different types of CNS cancer ..................... 51
3.1. Single dose 60 cell lines assay of compounds 1c-6c ............................ 60
3.2. Single dose 60 cell lines assay of compounds 7c-9c ............................ 62
3.3. Anticancer activities (GI50) against melanoma ....................................... 65
3.4. Anticancer activities (GI50) against colon cancer ................................... 66
3.5. Anticancer activities (GI50) against non-small cell lung cancer .............. 67
3.6. Anticancer activities (GI50) against CNS cancer .................................... 68
3.7. Anticancer activities (LC50) against melanoma ...................................... 69
3.8. Anticancer activities (LC50) against colon cancer .................................. 70
3.9. Anticancer activities (LC50) against non-small cell lung cancer ............. 71
3.10. Anticancer activities (LC50) against CNS cancer .................................. 72
3.11. Comparison of antibacterial and anticancer activities ........................... 75

xi

4.1. IC50 values for compound 2c, etoposide, and NQM108 ......................... 91
4.2. Comparison of redox potentials with antibacterial and anticancer
activities ............................................................................................... 109
4.3. Summary of cyclic voltammetry ........................................................... 110
5.1. Antibacterial activity of MCAAs (µg/mL) ............................................. 131
5.2. Antibacterial activity of MCAAs (µg/mL) ............................................. 133

xii

LIST OF FIGURES
Figure
1.

Page
Top 10 causes of death in the United States during 1900 (Left)
and 1997 (Right) .................................................................................. 2

1.1.

Coenzyme Q10 (right) and Electron Transport Chain (left) ................... 4

1.2.

Commercial drugs containing quinone motif ......................................... 6

1.3.

1,4-naphthoquinone (A); 1,2-naphthoquinone (B) ................................. 5

1.4.

Vitamin K series .................................................................................... 7

1.5.

1,4-naphthoquinone analogs showing diverse bioactivities .................. 8

1.6.

Patented antibacterial agent from our lab (WO2012021409 A30). ....... 9

1.7.

Quinone scaffolds present in nature ................................................... 10

1.8.

Structure of molecular oxygen and common ROS .............................. 11

1.9.

Reduction of ROS by glutathione ........................................................ 12

1.10. Mitochondria showing ROS generation............................................... 13
1.11. Selective killing of cancer cells by ROS .............................................. 14
1.12. General scheme for quinone oxidation and reduction showing the
formation of semiquinone/hydroquinone and ROS ............................. 15
1.13. Ascorbate mediated quinone oxidation and reduction showing the
formation of semiquinone/hydroquinone and ROS ............................. 16

xiii

1.14. Anthracenediones analogs ................................................................. 18
1.15. Structure of mitomycin C..................................................................... 18
1.16. Mechanism of mitomycin C activation and DNA alkylation ................. 19
1.17. Streptonigrin and related compounds ................................................. 20
1.18. Seven known members of criobstatin family ....................................... 21
1.19. Naturally occurring antibacterial 1,4-napthoquinone analogs ....................22
1.20. MIC values against (a) S.aureus, (b) E. Coli, and (c) Compound
Structure ............................................................................................. 23
1.21. Fragmentation of intermediate to form different heterocycles ............. 25
1.22. Reduction of tetrazolium salt to formazone during MTT assay ........... 26
1.23. Cell cycles (Left) and layout of cell cycle analysis plot from flow
cytometry (Right) ................................................................................ 27
1.24. Different stages of Apoptosis: (Left) normal cell, PS is still
located inside the plasma membrane; (Center) early apoptotic
cell with Annexin V-FITC on exposed PS, (Right) Late apoptosis
with ruptured plasma membrane, PI bound to DNA and Annexin
V-FITC bound on PS........................................................................... 28
1.25. Mechanism of ROS detection by DCFDA dye .................................... 29
1.26. Mechanism of detection of glutathione depletion ................................ 30

xiv

1.27. The structure of rhodamine 123 (Left) and mitochondrial
membrane showing membrane potential and site of distribution
of rhodamine123 (Right). .................................................................... 31
1.28. Mechanism of detection of caspase activity ........................................ 31
3.1.

Cationic anthraquinone analogs. ......................................................... 57

3.2.

Comparison of mean cell growth percentage ...................................... 64

3.3.

Comparison of average GI50 (nM)........................................................ 64

3.4.

Dialkyled cationic anthraquinone analogs ........................................... 73

4.1.

(A) FDA-approved anticancer drugs containing quinone motifs;
(B) Cationic 1,4-naphthoquinone analogs from our laboratory............ 88

4.2.

2c, NQM108, and etoposide dose-response curves ........................... 91

4.3.

Cell cycle analysis of A549 cells incubated with 2c for 24 h (A & B) ... 93

4.4.

Annexin-V/PI assay for apoptosis (A and B),* = P ≤ 0.05,
and **** = P ≤ 0.0001 ......................................................................... 95

4.5.

(A) Morphological changes in A549 cells treated with 2c; (B)
morphological changes in the A549 cell nucleus and
mitochondria treated with 2c ............................................................... 96

4.6.

Reactive oxygen production in A549 after incubation of 2c
(A and B), and NQM108 (C) for 4 h. * = P ≤ 0.05; ** = P ≤ 0.01,

xv

and **** = P ≤ 0.0001 .......................................................................... 98
4.7.

Glutathione depletion at different time intervals. ** = P ≤ 0.01,
and **** = P ≤ 0.0001 ........................................................................ 100

4.8.

Decrease in mitochondrial membrane potential in A549 cells at
different concentrations of 2c (A and B). *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001, and ****P ≤ 0.0001. ..................................................... 102

4.9.

Decrease in mitochondrial membrane potential in A549 cells
at different concentrations of NQM108 (C and D) *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001 .................................... 103

4.10. (A) Caspase-3 release at different time intervals
(1 h, 4 h, 12 h and 48 h); (B) caspase-3 release at different
concentrations (0 μM, 0.01 μM, 0.1 μM, 1.0 μM, and 10.0 μM).
* = P ≤ 0.05, and ** = P ≤ 0.01 .......................................................... 105
4.11. DNA cleavage experiment with different concentration of 1c
(Top); DNA cleavage experiment for other CAAs at 240 M
concentration (Bottom)...................................................................... 112
5.1.

Cationic amphiphiles ......................................................................... 126

5.2.

Structural comparison of CAAs from our laboratory .......................... 127

5.3.

Candida albicans, control (top). Candida albicans incubated
with NQM123C10 for 1h (bottom).. ................................................... 134

xvi

5.4.

Fusarium graminerium single hypha experiment Control (top).
Incubated with NQM123C10 for 1h (bottom).. .................................. 134

5.5.

Cytoxicity assya of all MCAA analogs ............................................... 135

xvii

LIST OF SCHEMES
Scheme

Page

2.1.

Two-step synthesis of compound 4 .................................................... 43

2.2.

One-pot synthesis of compound 4 ...................................................... 45

2.3.

Mechanism for multiple product formation in scheme 2 ...................... 47

2.4.

New Method of synthesis of compound NQM111 ............................... 48

2.5.

Proposed mechanism of NQM111 formation from 4a’ ........................ 48

2.6.

Proposed mechanism of NQM111 formation from 4c’ ........................ 49

3.1.

Synthesis of cationic anthraquinone analogs ...................................... 58

3.2.

Synthesis of cationic anthraquinone analogs with substituted
aryl groups .......................................................................................... 59

3.3.

Synthesis of cationic anthraquinone analogs with substituted
aryl groups (aryl group substituted with multiple methoxy group). ...... 61

4.1.

Summary of Synthesis of anticancer cationic anthraquinone
analogs .............................................................................................. 89

4.2.

Process of formation of semi-quinone and hydroquinone ................. 107

4.3.

Proposed mechanism of ROS formation in ETS by cationic
anthraquinone analogs ..................................................................... 108

5.1.

Synthesis of multi-cationic CAAs ...................................................... 129

xviii

LIST OF ABBREVIATIONS

ΔΨm: Mitochondrial membrane potential
APCI: Atmospheric pressure chemical ionization
ATP: Adenosine triphosphate
CAA: Cationic anthraquinone analog
CAT: Catalase
CIB: Center for integrated biosystems
CNS: Central nervous system
DAPI: 4′,6-Diamidino-2-phenylindole dihydrochloride
DCFDA-AM: 2’,7’-dichlorofluorescein diacetate
DMF: Dimethyl foramide
DMEM: Dulbecco's Modified Eagle's medium
DMSO: Dimethyl sulfoxide
DNA: Deoxyribonucleic acid
DTP: Developmental therapeutic program
EDTA: Ethylenediaminetetraacetic acid
ESI: Electron spray ionization
ETC: Electron transport chain
EU: European Union
FACS: Fluorescence activated cell sorting
FBS: Fetal bovine serum
FDA: Food and drug administration
FBS: Fetal bovine serum

xix

G+: Gram positive
G-: Gram negative
GI50: Growth inhibition by 50%
GPX: Glutathione peroxidase
GSH: Glutathione
IARC: International agency for research on cancer
LC50: Lethal concentration for 50%
MCAA: Multi-cationic anthraquinone analog
MCB: Monochlorobimane
MIC: Minimum inhibitory concentration
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NCI: National cancer institute
NMR: Nuclear magnetic resonance
NQ1: Quinone oxidoreductase 1
PBS: Phosphate-buffered saline
PI: Propidium Iodide
PS: Phosphatidylserine
Q10: Ubiquinone
QAC: Quaternary ammonium complex
ROS: Reactive oxygen species
SAR: Structure activity relationship TB: Tuberculosis
SOD: Superoxide dismutase
SQR: Semiquinone radical
TB: Tuberculosis

xx

TBAF: Tetrabutylammonium hexafluorophosphate
TLC: Thin layer chromatography

xxi

LIST OF SPECTRA
Spectrum

1.

Page

1

H NMR of 1-benzyl-1H-naphtho[2,3-d][1,2,3]triazole-4,

9-dione (4a’) .................................................................................... 145
2.

1

H NMR of 1,3-dimethyl-4,9-dioxo-4,9-dihydro-1H-naphtho

[2,3-d][1,2,3]triazol-3-ium triflate (NQM111)...................................... 146
3.

1

H NMR 1-((2-methoxyethoxy)methyl)-1H-naphtho[2,3-d][1,2,3]

triazole-4,9-dione (4c’) ..................................................................... 147
4.

13

C NMRof 1-((2-methoxyethoxy)methyl)-1H-

naphtho[2,3-d][1,2,3]triazole-4,9-dione (4c’) ..................................... 148
5.

1

H NMR of 1-phenyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-

dione (1b) ........................................................................................ 149
6.

13

C NMR of 1-phenyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-

Dione (1b) ...................................................................................... 150
7.

1

H NMR of 3-methyl-4,9-dioxo-1-phenyl-4,9-dihydro-1H-naphtho

[2,3-d][ 1,2,3]triazol-3-ium triflate (1c) ............................................... 151
8.

13

C NMR of 3-methyl-4,9-dioxo-1-phenyl-4,9-dihydro-1H-naphtho

[2,3-d][ 1,2,3]triazol-3-ium triflate (1c) ............................................... 152
9.

1

H NMR of 3-methyl-4,9-dioxo-1-(4-methoxyphenyl)-3-methyl

-4,9-dioxo-1-phenyl-4,9-dihydro-1H-naphtho[2,3-d][ 1,2,3]
triazol-3-ium triflate (2c) .................................................................... 153
10.

13

C NMR of 3-methyl-4,9-dioxo-1-(4-methoxyphenyl)-3-methyl

xxii

-4,9-dioxo-1-phenyl-4,9-dihydro-1H-naphtho[2,3-d][ 1,2,3]
triazol-3-ium triflate (2c) .................................................................... 154
11.

1

H NMR of 1-(p-tolyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-

dione (3b) ......................................................................................... 155
12.

13

C NMR of 1-(p-tolyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-

dione (3b) ........................................................................................ 156
13.

1

H NMR of 3-methyl-4,9-dioxo-1-(p-tolyl)-4,9-dihydro-1H-

naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (3c) ................................. 157
14.

13

C NMR of 3-methyl-4,9-dioxo-1-(p-tolyl)-4,9-dihydro-1H-

naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (3c) ................................. 158
15.

1

H NMR of 1-(4-(trifluoromethyl)phenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9- dione (4b)............................................................ 159
16.

13

C NMR of 1-(4-(trifluoromethyl)phenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9- dione (4b)............................................................ 160
17.

1

H NMR of 3-methyl-4,9-dioxo-1-(4-(trifluoromethyl)phenyl)

-4,9-dihydro-1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (4c) ....... 161
18.

13

C NMR of 3-methyl-4,9-dioxo-1-(4-(trifluoromethyl)phenyl)-

4,9-dihydro-1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (4c) ........ 162
19.

1

H NMR of 1-(4-chlorophenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9- dione (5b)............................................................ 163
20.

13

C NMR of 1-(4-(chlorophenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9- dione (5b)............................................................ 164
21.

1

H NMR of 3-methyl-4,9-dioxo-1-(4-(chlorophenyl)-4,9-dihydro-

1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (5c) ........................... 165

xxiii

22.

13

C NMR of 3-methyl-4,9-dioxo-1-(4-(chlorophenyl)-4,9-

dihydro-1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (5c) .............. 166
23.

1

H NMR of 1-(4-fluorophenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9- dione (6b)............................................................ 167
24.

13

C NMR of 1-(4-fluorophenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9- dione (6b)............................................................ 168
25.

1

H NMR of 3-methyl-4,9-dioxo-1-(4-(fluorophenyl)-4,9-dihydro-

1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (6c) ........................... 169
26.

13

C NMR of 3-methyl-4,9-dioxo-1-(4-(fluorophenyl)-

4,9-dihydro-1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (6c) ........ 170
27.

1

H NMR of 1-(3,5-dimethoxyphenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9- dione (7b)............................................................ 171
28.

13

C NMR of 1-(3,5-dimethoxyphenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9- dione (7b)............................................................ 172
29.

1

H NMR of 3-methyl-4,9-dioxo-1-(3,5-dimethoxyphenyl

-4,9-dihydro-1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (7c) ....... 173
30.

13

C NMR of 3-methyl-4,9-dioxo-1-(3,5-dimethoxyphenyl 4,9-

dihydro-1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (7c) ............. 174
31.

1

H NMR of 1-(3,4,5-trimethoxyphenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9- dione (8b)............................................................ 175
32.

1

3C NMR of 1-(3,4,5-trimethoxyphenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9- dione (8b)............................................................ 176
33.

1

H NMR of 3-methyl-4,9-dioxo-1-(3,4,5-trimethoxyphenyl

4,9-dihydro-1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (8c) ........ 177

xxiv

34.

13

C NMR of 3-methyl-4,9-dioxo-1-(3,4,5-trimethoxyphenyl

4,9-dihydro-1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (8c) ....... 178
35.

1

H NMR of 1-(3,4,-dimethoxyphenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9-dione (9b)............................................................. 179
36.

13

C NMR of 1-(3,4-dimethoxyphenyl)-1H-naphtho[2,3-d]

[1,2,3]triazole-4,9-dione (9b)............................................................. 180
37.

1

H NMR of 3-methyl-4,9-dioxo-1-(3,4-dimethoxyphenyl 4,9-

dihydro-1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (9c) .............. 181
38.

13

C NMR of 3-methyl-4,9-dioxo-1-(3,4-dimethoxyphenyl 4,9-

dihydro-1H-naphtho [2,3-d][ 1,2,3]triazol-3-ium triflate (9c) .............. 182
39.

1

H NMR of 1,1'-(hexane-1,6-diyl)bis(1H-naphtho[2,3-d][1,2,3]

triazole-4,9-dione) (NQ123) .............................................................. 183
40.

13

C NMR of 1,1'-(hexane-1,6-diyl)bis(1H-naphtho[2,3-d]

[1,2,3]triazole-4,9-dione) (NQ123) .................................................... 184
41.

1

H NMR of 1,1'-(hexane-1,6-diyl)bis(3-methyl-4,9-dioxo-

4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C1) ......................................................................... 185
42.

13

C NMR of 1,1'-(hexane-1,6-diyl)bis(3-methyl-4,9-dioxo-

4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C1) .......................................................................... 186
43.

1

H NMR of 1,1'-(hexane-1,6-diyl)bis(3-ethyl-4,9-dioxo-4,9-

dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C2) .......................................................................... 187
44.

13

C NMR of 1,1'-(hexane-1,6-diyl)bis(3-ethyl-4,9-dioxo-

xxv

4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C2) .......................................................................... 188
45.

1

H NMR of 1,1'-(hexane-1,6-diyl)bis(3-butyl-4,9-dioxo-

4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C4) .......................................................................... 189
46.

13

C NMR of 1,1'-(hexane-1,6-diyl)bis(3-butyl-4,9-dioxo-

4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C4) .......................................................................... 190
47.

1

H NMR of 1,1'-(hexane-1,6-diyl)bis(3-hexyl-4,9-dioxo-

4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C6) .......................................................................... 191
48.

13

C NMR of 1,1'-(hexane-1,6-diyl)bis(3-hexyl-4,9-dioxo-

4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C6) .......................................................................... 192
49.

1

H NMR of 1,1'-(hexane-1,6-diyl)bis(3-octyl-4,9-dioxo-

4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C8) .......................................................................... 193
50.

13

C NMR of 1,1'-(hexane-1,6-diyl)bis(3-octyl-4,9-dioxo-

4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C8) .......................................................................... 194
51.

1

H NMR of 1,1'-(hexane-1,6-diyl)bis(3-decyl-4,9-dioxo-4,9-

dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C10) ........................................................................ 195
52.

13

C NMR of 1,1'-(hexane-1,6-diyl)bis(3-decyl-4,9-dioxo-4,9-

xxvi

dihydro-1H-naphtho[2,3-d][1,2,3]triazol-3-ium)
triflate (NQM123C10) ........................................................................ 196

xxvii

LIST OF CYCLIC VOLTAMMOGRAM

Voltammogram

Page

1.

Voltammogram for compound 1c ........................................................ 198

2.

Voltammogram for compound 2c ........................................................ 199

3.

Voltammogram for compound 3c ........................................................ 200

4.

Voltammogram for compound 4c ........................................................ 201

5.

Voltammogram for compound 5c ........................................................ 202

6.

Voltammogram for compound 6c ........................................................ 203

7.

Voltammogram for compound 7c ........................................................ 204

8.

Voltammogram for compound 8c ........................................................ 205

9.

Voltammogram for compound 9c ........................................................ 206

1

CHAPTER 1
GENERAL INTRODUCTION

The development of therapeutic agents for the treatment, and
prevention of diseases, and to relieve pain has played a critical role to pave
the pathway for the practice of modern medicine. Over many centuries,
medicines have been discovered and used in the form of crude extracts or
dried parts of plants and animal products.1 People in different civilizations
used plants such as poppy, henbane, mandrake, camphor, ginseng, jimson
weed, rhubarb, and aloe, for over 4000 years for folk medicine.2 Some of
these plants are still being used as a traditional medicine. A systematic
discovery and development (use of active chemical ingredient as a medicine
rather than plant extracts), took place only after the discovery of prontosil by
Gerhard Domagk in 1930s, and penicillin by Alexander Fleming in 1928. 3
Before the discovery of antibiotics, infectious diseases were one of the
biggest blights on the human history. In 1900, one-third of all deaths in the
United States was caused by either pneumonia, tuberculosis, or diarrhea.4
Nowadays, out of these three diseases, pneumonia is the only top ten cause
of death in the United States. The major deaths are resulting from other
conditions such as cardiovascular disease and cancer.4 Since 1999, cancer
has been the leading cause of death in the United States for individuals less
than 85 years of age.5
Even though the mortality rate caused by infectious diseases is
decreasing, the rate of infections caused by those pathogens and the
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discovery of new infectious diseases are not decreasing. Between 1940 and
2004, a staggering 335 new infectious diseases were discovered, and it is
estimated that three new diseases are being identified every couple of years. 6

Figure 1. Top 10 causes of death in the United States during 1900 (top) and
1997 (bottom)4

Worldwide 13.7 million people are infected with active tuberculosis
(TB), and 2 billion people are infected with an inactive form of TB.7 247 million
people are infected with malaria every year.7 Similarly, according to the
International Agency for Research on Cancer (IARC), there were 14.1 million
new cancer cases and 8.2 million cancer related deaths worldwide in 2012.8
So far, there are more than 200 types of known cancers. The rise of drugresistant microbes and cancers, which used to be curable in the past,
complicated the situation even more. Through mutation or genetic exchange,
infectious agents can develop resistance to available drugs and evolve into
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new deadly strains. Therefore, there is an imminent need for the development
of new antimicrobial agents.
Extraction of active components from natural products and chemical
synthesis of therapeutic agents are the two major sources of drug discovery
for anticancer and antimicrobial agents. Plants and animals produce many
therapeutic agents as a physiological byproduct or as a defense mechanism.
Since most of the naturally occurring compounds have been in nature for a
long time and been exposed to several living things, chances are very high
that some of the species have already developed resistance or will develop
resistance soon. In this situation, development of antimicrobial and anticancer
agents by chemical synthesis comes in as a very effective tool. The
chemically synthesized drug candidates are newly exposed to the
environment, and it will take much longer to develop resistance when
compared to naturally occurring drugs. Eventually, most of the antimicrobial
compounds will have some resistance. It is estimated that the annual resistant
infections cost about USD 20 billion in excess health care cost in USA9 and
€1.5 billion in the European Union (EU).10 There is an ongoing and neverending battle between drug development and drug resistance by microbes,
and hence, we need to develop new antimicrobial agents constantly. We can
achieve this goal only by chemical modifications to already known scaffolds
since the discovery of new bioactive lead compounds is very rare.
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1.

Quinones
Quinones are one of the most popular scaffolds for the synthetic

chemist to use as a core structure. They are a vast class of compounds,
widely distributed in nature, and occur abundantly in plants, animals, and
microbes. They are often used as pharmaceutical drugs (anticancer,11 antiinflammatories,12 antibacterial,13 antifungal,13a antiplatelet,14 neuroprotective
agents,15 and laxative agents16), daily nutrition,17 dyes,18 chemical reagents,19
and as a charge carrier in a flow cell battery.20 Quinone motifs are responsible
for some of the key role in the biological system. Ubiquinone (Q10), a 1,4benzoquinone derivative with a 50 carbon isoprenoid side chain, plays an
essential role in aerobic respiration to generate adenosine triphosphate (ATP)
(Figure 1.1). Q10 is a part of the electron transport chain (ETC), where it acts
as a mobile electron carrier, transferring electrons from complex I to complex
III, or from complex II to complex III (Figure 1.1).

Figure 1.1. Coenzyme Q10 (left) and Electron Transport Chain (right)21
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Quinone moieties have not only attracted enormous research interests; they
have also resulted into several FDA approved commercial drugs. Some of
the quinone based FDA approved drugs with different bioactivities are listed in
Figure 1.2.

1.1.

Naphthoquinone
Naphthoquinone is one of the most important subclasses of quinone.

They are organic molecules derived from naphthalene. They are planar in
geometry and contain aromatic ring fused to quinone. 1,2-naphthoquinone
and 1,4-napthoquinone are the two types of naphthoquinone core present in
nature (Figure 1.3). The prefix 1,2 or 1,4 represents the position of the ketone
functional groups.

Figure 1.3. 1,4-naphthoquinone (A); 1,2-naphthoquinone (B)

They are present in various parts of plants such as leaves, flowers,
roots, barks, and woods. Aside from being used as antimicrobial agents22 and
anticancer agents,23 molecules bearing naphthoquinone scaffolds have also
been employed as inhibitors against vitamin K-dependent carboxylase,24
protein kinase,25 coenzyme Q;26 as laxative;27 and as a growth stimulator for
bifidobacteria.28
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Figure 1.2. Commercial drugs containing quinone motif.
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Vitamin K, a representative class of 1,4-naphthoquinone which
includes vitamin K1, vitamin K2, and vitamin K3 play important roles in the
biological system. Vitamin K1 is a naturally occurring molecule and also
known as phylloquinone (Figure 1.4). It is required for blood coagulation.29
Vitamin K2 or menaquinone (Figure 1.4) is of vital importance for bone
health.30 Vitamin K3 or menadione is a synthetic form and used as a quinone
model for in vivo studies. In combination with ascorbic acid, it is under clinical
trial as an anticancer agent.

Figure 1.4. Vitamin K series

The naphthoquinone core structure is fascinating for medicinal
research because even a small change of substitution can drastically change
its biological activities (Figure 1.5).
Our laboratory is dedicated to synthesizing small bioactive molecules
by structural modification of 1,4-naphthoquinone. We use the classical
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approach of drug design and development, where we screen several newly
synthesized

Figure 1.5. 1,4-naphthoquinone analogs showing diverse bioactivities

compounds for their biological activities. This approach of drug design is one
of the most successful methods to develop lead compounds, and has led to
several new FDA approved drugs. Several bioactive analogs of 1,4naphthoquinonewere already synthesized via azide chemistry.11c, 11d, 31 By
using a simple [3+2] cycloaddition with azide and oxidation, followed by
methylation gives the product in very high yield. In all the synthetic steps,
these compounds do not require any cumbersome purification process via
column chromatography. High overall yields and no requirement for column
chromatography make them excellent candidates for commercialization. Once
we characterize compounds, we test them against cancer cell lines and
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several pathogenic microbes. Once we hit an active lead compound, we carry
out structure-activity relationships (SAR) to synthesize analogs that are even
more potent. Several patented bioactive compounds are synthesized in our
laboratory from this pathway (Figure 1.6).

Figure 1.6. Patented antibacterial agent from our lab (WO2012021409 A30).

Benzoquinone and anthraquinone are another very similar quinone
motifs present in nature. Benzoquinone lacks aromatic benzene ring attached
to 1,4-naphthoquinone while anthraquinone has an extra aromatic ring
attached to 2,4 position. Even though we use 1,4-naphthoquinone core as the
starting material, our final products contain an aromatic triazole ring attached
to the 2,4 positions, resulting in a structure very similar to anthraquinone.
Therefore, we called these analogs anthraquinone analogs. These
anthraquinone analogs are alkylated to form cationic salts, hence abbreviated
as cationic anthraquinone analog (CAA).
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Figure 1.7. Quinone scaffolds present in nature

1.2.

Understanding cancer and naphthoquinone-based anticancer drugs

1.2.1. Oxidative stress
Oxidative stress is defined as the imbalance between reactive oxygen
species (ROS) and antioxidant defenses. The concentration of ROS is highly
regulated in cells. The imbalance is usually caused by the overproduction of
ROS, which overcomes the antioxidant defenses, and accumulates inside
cells. Once accumulated, they can damage and alter different cellular
components such as proteins, lipids, DNA, and RNA.32 Even though the
higher concentration of ROS is harmful; a lower concentration is required for a
subcellular process such as enzyme activation, gene transduction, disulfide
bond formation.33

1.2.2. Reactive oxygen species (ROS)
ROS is a group of highly reactive free radical derivatives of oxygen. It
includes superoxide radical anion, peroxides, hydroxyl radical and singlet
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oxygen (Figure 1.8). Superoxide radicals are the product of one-electron
reduction of molecular oxygen, which rapidly converts to hydrogen peroxide.34
Hydrogen peroxides are the least reactive among other ROS, so its lifetime in
cells is much longer than any other ROS.34

Figure 1.8. Structure of molecular oxygen and common ROS

1.2.3. ROS Sources and modulation inside the cell
ROS generation is a natural process, and they are by-products of the
oxidative phosphorylation in the mitochondria.35 In ETC (Figure 1.1), some of
the electrons can escape while transporting from ETC complex I to III or from
complex II to III via coenzyme Q10. The escaped electrons reduce molecular
oxygen forming highly reactive superoxide radical. It is estimated that up to
2% of oxygen consumed during ATP synthesis are reduced into ROS via this
pathway.36 Complex I is the most ROS-generating site as the highest number
of premature electrons leak from this complex. Enzymes such as cytochrome
P45s are also responsible for some of the ROS generated.
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Antioxidant defenses modulate ROS in cells. These radical scavengers
mostly involve enzymes and small molecules. Glutathione, superoxide
dismutase (SOD), glutathione peroxidase (GPX), catalase (CAT), vitamin E,
ascorbic acid, beta-carotene, and vitamin A are some of the examples.
Glutathione and thioredoxin scavenge ROS by the oxidation of dithiols; the
oxidized thiols are recycled back to reduced form by the corresponding
reductase (Figure 1.9).

Figure 1.9. Reduction of ROS by glutathione

The second method of ROS modulation is through an enzyme called
SOD, which rapidly catalyzes the formation of hydrogen peroxide from
superoxide radical. The hydrogen peroxide is then converted to neutral
oxygen and water by catalase. A representative diagram (Figure 1.10) below
shows a mitochondrial schematic of different functions associated with ROS
generation.
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Figure 1.10. Mitochondria showing ROS generation37

1.2.4. Level of ROS in cancer cell versus normal cell
Cancer cells have an elevated concentration of endogenous ROS
when compared to normal cells. They are rapidly dividing and metabolically
very active.
The elevated rate of metabolic activity in cancer cells requires more ATP than
normal cell lines. The extra metabolic burden on ETC leads to the formation of
elevated ROS level. It is also proposed that ROS can damage mitochondrial
DNA, which results in mutation. The mutation causes more electrons to
escape from ETC forming more ROS.

1.2.5. Mechanism of cell death involving quinone
The toxicities of quinones are mostly based on their ability to generate ROS
and to function as a Michael acceptor. The carbonyl groups on quinones allow
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Figure 1.11. Selective killing of cancer cells by ROS

acceptance of one or two electrons and protons forming semiquinone which in
turn reduces molecular oxygen, forming ROS. The strength that enzymes are
affected by naphthoquinone depends on the redox potential, molecular
structure, pH, quinone/enzyme ratio and the presence of oxygen. Some
studies have also shown that naphthoquinone may act as both an arylator and
a redox cycler.

1.2.5.1 Quinone Redox mechanism
1.2.5.1.1. Enzyme catalyzed redox process
Quinones undergo reductive activation by two major enzymes such as
cytochrome P450s and cytochrome P450 reductase. The bioreductive
activation can go with by 1 electron reduction process or by 2 electron
process. The 1 electron reduction of quinone forms semi-quinone, while 2
electron reduction forms dihydroquinone (Figure 1.12). The semiquinone or
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hydroquinone can be recycled back to the quinone under normal oxygen level
forming superoxide.

Figure 1.12. General scheme for quinone oxidation and reduction showing
the formation of semiquinone/hydroquinone and ROS.

Cytochrome P450 reductases are the main enzymes that catalyze
quinone reduction via the 1 electron process. Cytochrome P450 reductases
lack a metal center, so they can only reduce quinones by 1 electron at a time.
Cytochrome P450 enzymes contain an iron core, which activates quinone by
2 electron process using NADPH. Another enzyme called NAD(P)H: quinone
oxidoreductase 1 (NQ1), also reduces quinone by a 2-electron process
forming hydroquinone. This process is facilitated by cofactors such as FAD
and NAD(P)H. NQ1 activates Pro-drugs such as geldanamycin, mitomycin, βlapachone, and streptonigrin.

1.2.5.1.2. Non-enzymatic redox process
Quinones can also be activated non-enzymatically. An oxidant such as
ascorbate can oxidize quinone, forming semiquinone (Figure 1.13).
Menadione, a naphthoquinone derivate with ascorbate, is under clinical
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investigation for anticancer studies. Several studies have shown that
anthraquinones such as alizarin, dantron, mitoxantrone, and daunorubicin are
not activated by ascorbate. Therefore, it is possible that only a few quinones
are activated by ascorbate and may not be the principal mechanism of
quinone activation.

Figure 1.13. Ascorbate mediated quinone oxidation and reduction showing
the formation of semiquinone/hydroquinone and ROS.38

1.2.5.2. Quinone as a Michael acceptor
Quinone derivatives with open α,β-unsaturated ketones are vulnerable
to nucleophiles via Michael addition. It is already reported that menadione
covalently binds to β-93 thiol groups of human hemoglobin via Michael
addition forming menadione thioester.39 The process of thioester formation is
related to menadione-induced hemolysis of erythrocytes. Doxorubicin and
daunorubicin can also alkylate DNA and other nucleophilic macromolecules
via Michael addition.40 These compounds do not have an α, β-unsaturated
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site, but forms after bio-activation. They undergo reductive cleavage of sugar
moiety forming an α, β-unsaturated site at ring D.40

1.2.6. Quinone based drugs in cancer treatment
1.2.6.1. Anthracyclines
Anthracyclines are antibiotics used in cancer chemotherapy, and they
are one of the most successful cancer treatments ever developed. They are
natural products and derived from Streptomyces. They are active against
leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder, and lung
cancers. The dose-dependent cardiotoxicity often limits their usefulness and
are often given with dexrazoxane, an iron chelator as a cardioprotective
agent. Daunorubicin, idarubicin, doxorubicin, epirubicin, and valrubicin are
the FDA approved anthracyclines for chemotherapy (Figure 1.3).

1.2.6.2. Anthracenediones
Anthracenediones are synthetic analogs of anthracyclines. They lack a
ring D in anthracycline and a sugar moiety. These analogs of anthracyclines
were developed as a less cardiotoxic form of anthracycline. Pixantrone and
mitoxantrone are an example of two anthracenediones, currently used in the
market. Mitoxantrone is mostly used to treat metastatic breast cancer, acute
myeloid leukemia, and non-Hodgkin's lymphoma. Mitoxantrone intercalates
into DNA and instigates DNA crosslinking and DNA strand break. It is also
known to inhibit topoisomerase II.
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Figure 1.14. Anthracenedione analogs

1.2.6.3. Mitomycin C and its analogs
Mitomycins are derived from Streptomyces species. Mitomycin C is
one of the major compounds from this class, and used as both antibiotic and
anticancer. Mitomycin C is derived from Streptomyces caespitosus. Mitomycin
C is a bioreductive alkylating agent, which generates electrophile upon
reduction, and bind covalently to cellular macromolecules. A bioreductive
activation process of mitomycin C by enzyme NQ01 and DNA crosslinking is
shown in Figure 1.16.

Figure 1.15. Structure of Mitomycin C
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Figure 1.16. Mechanism of mitomycin C activation and DNA alkylation

1.2.6.4. Streptonigrin and related compounds
Streptonigrin is a metal binding antibiotic antitumor agent isolated from
Streptomyces flocculus.41 It shows a broad range of anticancer activity
including breast, lung, lymphoma, melanoma, as well as head and neck
cancer.42 It inhibits DNA and RNA synthesis, breaks DNA strands, induces
unscheduled DNA synthesis, forms DNA adducts, and also inhibits
topoisomerase II.41, 43 Streptonigrin produces DNA damaging effect by
autooxidation of the quinone moiety to semiquinone in the presence of
NADPH, which reduces molecular oxygen to free radical.44 Quinone moiety is
essential in Streptonigrin as antitumor activity was lost without quinone
moiety.45

20

Figure 1.17. Streptonigrin and related compounds

1.2.6.5 Cribostation
Cribostatins are isoquinoline quinones isolated from a sea sponge.46
So far, seven cribostatins have been isolated.47 All of the members were
isolated from Cribrochalina except Cribostation 7, which was isolated from
Petrosia sponge (Figure 1.18). All seven compounds possess antineoplastic
activity and IC50 ranges from 0.045-25 µM against murine leukemia cell line.47
These compounds also possess antibacterial and antifungal activities.
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Figure 1.18. Seven known members of the cribostatin family

1.3.

1,4-Naphthoquinone derivatives as antimicrobial agent
Various 1,4-naphthoquinone derivatives with antibacterial activity are

already known (Figure 1.19), e.g. plumagin, juglone, and lawsone, which are
naturally occurring naphthoquinone of plant origin. Alkannin, shikonin, and
their rivatives are other natural naphthoquinone products whose antimicrobial
activity has been widely investigated.
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Figure 1.19. Naturally occurring antibacterial 1,4-napthoquinone analogs48

Our laboratory has extensively published 1,4-napthoquinone based
antibacterial agents. These compounds are highly effective against S. aureus
with MIC value of 0.032 µg/mL. These compounds are shown to inhibit redox
processes at MIC level and disrupt membrane at the higher concentration.
By varying chain length at R and R’ position (Figure 1.20 C), several new
analogs were synthesized and studied their antibacterial effect on S. aureus
and E. Coli.

The effect of alkyl chain length on MIC value for both S. aureus

and E. Coli can be observed in Figure 1.20.

23

Figure 1.20. MIC values against (a) S. aureus, (b) E. coli , and (c) Compound
structure.
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1.4. Advantages of naphthoquinone derivatives via azide chemistry
[3+2] cycloaddition of azide with 1,4-naphthoquinone provides an
easy one step method to attach any functional group on naphthoquinone. The
protocol for [3+2] cycloaddition is well established, and several approaches
are already published to attach alkyl or aromatic groups. The reaction is
thermodynamically controlled; and depending on temperature or addition of
Lewis acid, several other biologically important heterocyclic molecules can be
synthesized (Figure 1.21),49 including indanedione, anthraquinone,
benzazepine, and aziridine. Even though a mixture of several products is
obtained from this method, our group has specialized into driving those
reactions to obtain one major product. It is done either by addition of Lewis
acid or using thermodynamic control. Figure 1.21 shows possible degradation
pathways of the intermediate to give different heterocyclic molecules.
Water solubility is another issue with many biologically active
molecules. For example, the anthraquinone motif has two benzene rings on
either side of quinone, and many anthraquinone drugs have poor solubility in
water. NQ component synthesized from the cycloaddition can be methylated
at N1 to form a cationic salt (NQM component), which enhances its water
solubility.
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1.5. Brief Introduction to the biological techniques used in this dissertation
1.5.1. Flow cytometry
Flow cytometry provides rapid physical and chemical characteristics of
a single cell as they pass through a narrow channel in a fluid stream through a
laser beam. The laser beam excites the fluorescently labeled cell and a
detector measures the fluorescence intensity. Multiple lasers can be used to
determine different cellular characteristics at the same time. It is a very rapid
technique, which can scan ~10,000 cells in less than a minute. The technique
is widely used in research with more than one-third of papers in the Journal of
Immunology include flow cytometric data.50

1.5.2. MTT assay
Use of MTT (3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium
bromide), is a very well-known assay for determination of cell viability.51 It is a
colorimetric assay for accessing cell metabolic activity. Under the defined
condition, NAD(P)H-dependent cellular oxidoreductase enzymes reduce
slightly yellow tetrazolium MTT dye into purple insoluble formazone.51 The
absorption measurement of formazone compared to control directly reflects
the cell viability.

Figure 1.22. Reduction of tetrazolium salt to formazone during MTT assay
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1.5.3. Cell cycle analysis
The cell cycle is defined as the period between the successive division
of a cell into two daughter cells. Eukaryotic cell division is divided into four
different phases (G1, S, G2, and M). During G1, cells prepare for DNA
replication and contain 2n chromosomes. During S2 phase, replication of DNA
occurs, and there is a broad distribution of DNA content. By the end of S2
phase, cells should contain 4n chromosomes. Now they enter G2 phase,
where they start to grow again for cell division. Once ready, they enter mitosis
and divide into two daughter cells. At different phases of cell cycle, various
cellular enzymes and machinery are specifically active. Cell cycle analysis
helps to identify cell cycle arrest. The analysis is based on DNA labeling with
propidium iodide (PI), a fluorescent dye. Flow cytometric analysis of cells
containing PI-labeled DNA generates a cell population histogram in respect to
PI fluorescent intensity.52 The amount of fluorescence is directly correlated to
DNA content in the cell or different phase of the cell.

Figure 1.23. Cell cycles (Left) and layout of cell cycle analysis plot from flow
cytometry (Right)
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1.5.4. FITC Annexin-V/PI Apoptosis assay
The process of apoptosis is a programmed cell death.53 It is a normal
physiologic process for the removal of unwanted cells. During this process,
translocation of membrane phosphatidylserine (PS) from the inner side of the
plasma membrane to the outer surface takes place.54 Annexin-V, a Ca2+dependent phospholipid-binding protein, has a high affinity for PS, and
fluorochrome-labeled Annexin-V can be used for the detection of exposed PS
using flow cytometry (A+).55 The assay is a double staining process where
propidium Iodide (PI), a membrane impermeable dye is also used to stain cell.
Since there is no compromise in membrane integrity, no PI can get into the
cell, thus no fluorescence from PI (PI-). In later stages of apoptosis, the
integrity of cell membrane is compromised. As a result, both Annexin-V and PI
fluorescence becomes positive.

Figure 1.24. Different stages of Apoptosis: (Left) normal cell, PS is still
located inside the plasma membrane; (Center) early apoptotic cell with
Annexin V-FITC on exposed PS, (Right) Late apoptosis with ruptured plasma
membrane, PI bound to DNA and Annexin V-FITC bound on PS
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1.5.5. ROS detection assay
The level of ROS in the cell can be detected using 2’,7’dichlorofluorescein diacetate (H2DCFDA-AM), which is a non-fluorescent
dye.56 H2DCFDA-HA is non-toxic and can penetrate cell membrane easily.
Once they get into the cell, cellular esterase cleaves this compound into
H2DCF dye, which is also a non-fluorescent. If any ROS species are
generated by the cell, these ROS can oxidize non-fluorescent dye into a
fluorescent DCF dye. Flow cytometry or fluorescent microscopy tool can be
used to detect the fluorescence intensity, which reflects the level of ROS
generated in that period.

Figure 1.25. Mechanism of ROS detection by DCFDA dye

1.5.6. Glutathione depletion assay
Glutathione plays a critical role in the cellular defense mechanism
against oxidative and nitrosative stress in the mammalian cell.57 In early
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stages of apoptosis, glutathione is diminished. The level of glutathione is
determined by reacting monochlorobimane (MCB), a thiol reactive
fluorescence dye (excitation/emission 380/461 nm).58 By incubating cell lysate
with MCB, the level of fluorescence intensity reflects the amount of
glutathione present.

Figure 1.26. Mechanism of detection of glutathione depletion

1.5.7. Mitochondrial membrane potential measurement
In response to the electrical potential across the inner mitochondrial
membrane, several cationic dyes distribute into the mitochondria
electrophoretically.59 Rhodamine 123, Mito Tracker Red, and Mito Tracker
Green are some examples of those dyes.60 Upon incubation of these dyes
with cells, the fluorescence intensity is directly proportional to the membrane
potential. The fluorescence intensity can be detected via fluorescence
microscopy or flow cytometry.
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ΔΨ

Rhodamine
123

Figure 1.27. The structure of rhodamine 123 (Left) and mitochondrial
membrane showing membrane potential and site of distribution of rhodamine
123 (Right).

1.5.8. Caspase-3 activity assay
Caspases are released during the early stages of apoptosis either by
the extrinsic or intrinsic pathways.61 The intrinsic pathway involves cellular
stress and changes to mitochondria that release cytochrome c. The caspase
cascade activation leads to the activation of activator caspase -3 and -7,
which in turn cleave many cellular death target proteins.62 In this assay, the
caspase-3 enzyme cleaves the substrate and converts it to fluorescence 7amino-4-methyl coumarin (Figure 1.28). The fluorescence intensity is
proportional to the activity of caspase-3.

Figure 1.28. Mechanism of detection of caspase activity
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CHAPTER 2
SAFE AND EASY ROUTE FOR THE SYNTHESIS OF 1,3-DIMETHYL-1,2,3TRIAZOLIUM SALT AND INVESTIGATION OF ITS ANTICANCER
ACTIVITIESa

2.1. Abstract
We have developed a new safe and easy route for the synthesis of 1,3dimethyl-1,2,3-triazolium derivatives. We have previously reported the
synthesis of 4,9-dioxo-1,3-dimethylnaphtho[2,3-d][1,2,3]triazol-3-ium chloride
from methylation of 1-methyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione. The
synthesis of 1-methyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione is inefficient
as a significant amount of by-product is formed that is difficult to separate and
also unsafe as it requires the use of hazardous methyl azide as a starting
material. It is, however, important to develop an improved method for the
synthesis of 4,9-dioxo-1,3-dimethylnaphtho[2,3-d][1,2,3]triazol-3-ium salt due
to its significant anticancer activities. Herein, we report a safe and convenient
route for the synthesis of this compound, which lead to more detailed
exploration of its profound anticancer activities. The compound synthesized in
this new method shows significant anticancer activities against melanoma,
colon cancer, non-small cell lung cancer and central nervous system (CNS)
cancer with GI50 values ranging from low μM to nM.

_________________
a
Adapted with permission from [Shrestha, J. P.; Chang, C. W., Bioorg Med
Chem Lett 2013, 23 (21), 5909-11.] Copyright 2013. Elsevier B.V.
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2.2. Introduction
1,3-Dipolar cycloaddition of azides has attracted considerable interest
due to its potential applications in various areas.1 This reaction is typically
carried out by reacting alkynes with azides leading to the formation of 1,2,3triazoles.2 In a similar fashion, we have reported the synthesis of 1-alkyl-1Hnaphtho[2,3-d][1,2,3]triazole-4,9-diones, 4 via a tandem
cycloaddition/oxidation of 1,4-naphthoquinone, 1 and alkyl azides, 3 ( Scheme
2.1).3 Further alkylation of the cycloaddition/oxidation adducts using alkyl
triflate, 5 forms the 4,9-dioxo-1,3-dialkylnaphtho[2,3-d][1,2,3]triazol-3-ium
salts, 6 which can be viewed as cationic anthraquinone analogs.4

Scheme 2.1. Two-step synthesis of compound 4

Several of the cationic anthraquinone analogs exert interesting
biological activities ranging from antibacterial, antifungal to anticancer. Except
methyl azide and ethyl azide, the alkyl azides employed for this synthesis
were prepared from a nucleophilic substitution of sodium azide and the
corresponding alkyl halides, 2. Since small organic azides are known to be

44

explosive, we used methyl and ethyl 1-bromoacetate as the surrogate of
methyl or ethyl halides.5 This method is, however, inefficient which offers a
mixture of desired product and by-product. This mixture is hard to separate
and not possible to scale-up.

2.3. Design and Synthesis of 1,3-dimethyl-1,2,3-triazolium salt via new route
In an attempt to resolve this problem, we have previously developed an
alternative one-pot approach for the synthesis of the same cationic
compounds by generating alkyl azides in situ (Scheme 2.2).5-6 This method
has the shortcoming of generating by-product 7, which is hard to be separated
from the desired product, 4. Also from this study, a particular cationic
anthraquinone analog, 4,9-dioxo-1,3-dimethylnaphtho[2,3-d][1,2,3]triazol-3ium (R=R'=Me) was noted to manifest strong anticancer activities, in particular
against melanoma, colon cancer, non-small cell lung cancer and central
nervous system (CNS) cancer. Thus, there is an imminent need for an
efficient and safer synthetic approach for the synthesis of this particular
compound.
Alkyl azides that have the ratio of the sum of carbon and oxygen
atoms to nitrogen atoms lower than three are considered too reactive or
explosive and cannot be safely isolated.7 Therefore, 1,2,3-triazole substituted
with shorter alkyl chains, such as methyl or ethyl, cannot be safely
synthesized by using methyl azide or ethyl azide. In an effort to expand the
library of cationic anthraquinone
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analogs, we were surprised to find out that, upon methylation of a triazole
adduct,

Scheme 2.2. One-pot synthesis of compound 4

1-p-methoxybenzyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione, 4a’, an
unexpected product, NQM111 was obtained in good yield (Scheme 2.3).
However, same methylation of 1-benzyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9dione, 4b’,5 yielded the expected product, 9 rather than compound NQM111.
Therefore, we proposed that the electron-donating effect of p-methoxy render
the p-methoxybenzyl group a good leaving group during methylation
( Scheme 2.4). The resulted 1-methyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9dione, 10,5 can then be further methylated in the presence of excess MeOTf
to form NQM111. Although no attempt has been made to isolate
compound 10 during this process, we have previously demonstrated that
NQM111 can be synthesized by methylation of compound 10 using MeOTf.4a
The relationship between electron-donating effect and leaving group
capability was re-exemplified in another compound 4c’ containing a 2-
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methoxyethoxymethyl group at the N-1 position (Scheme 2.5). Upon
methylation using methyl triflate, NQM111 was also obtained in good yield.
This reaction proceeded, presumably, via similar mechanism and
intermediate. In both syntheses, the initial cycloaddition/oxidation starts by
using p-methoxybenzyl azide or 2-methoxyethoxymethyl azide rather than
hazardous methyl azide and thus, is superior in providing NQM111. In fact,
both of these syntheses can provide 1–2 g of NQM111 in one batch. When
necessary, the counterion, triflate can be exchanged for chloride using Dowex
1X (Cl−) resin.

2.4. Anticancer Activity of NQM111
Following the success in the safe and scale-up synthesis of
compound NQM111, more detailed investigation of the anticancer activities
of NQM111 was conducted through the Developmental Therapeutic Program
(DTP) of National Cancer Institute (NCI). Compound NQM111 is particularly
active against melanoma, colon cancer, non-small cell lung cancer and
central nervous system (CNS) cancer with GI50 (50% growth inhibition) values
ranging from low μM to nM (Table 2.1-2.4).8 Continuing investigation of the
anticancer activity of NQM111 is currently being carried out also by NCI.
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Scheme 2.4. New Method of synthesis of compound NQM111

Scheme 2.5 Proposed mechanism of NQM111 formation from 4a’
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Scheme 2.6. Proposed mechanism of NQM111 formation from 4c’

Table 2.1: GI50 values of NQM111 for different types of melanoma
Melanoma

GI50 (µM)

LOX IMVI (Malignant)

0.50

MALME-3M (Malignant)

0.15

M14

0.68

MDA-MB-435 (Adenocarcinoma)

0.20

SK-MEL-2 (Malignant)

1.57

SK-MEL-28 (Malignant)

1.61

SK-MEL-5 (Malignant)

0.38

UACC-257

1.79
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Table 2.2: GI50 values of NQM111 for different types of colon cancer
Colon Cancer

GI50 (µM)

COLO 205 (Adenocarcinoma)

1.01

HCC-2998 (Carcinoma)

1.24

HCT-116 (Carcinoma)

0.68

HCT-15 (Adenocarcinoma)

1.61

HT29 (Adenocarcinoma)

1.14

KM12 (Adenocarcinoma)

0.79

SW-620 (Adenocaracinoma)

1.15

Table 2.3: GI50 values of NQM111 for different types of non-small cell
lung cancers
Non-small Cell Lung Cancers

GI50 (µM)

A549/ATCC (Adenocarcinoma)

0.32

EKVX (Adenocarcinoma)

1.21

HOP-62 (Adenocarcinoma)

1.54

NCI-H226 (Squamous)

0.51

NCI-H23 (Adenocarcinoma)

0.62

NCI-H322M (Carcinoma)

0.28

NCI-H460 (Large cell carcinoma)

0.30

NCI-H522 (Adenocarcinoma)

1.41
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Table 2.4: GI50 values of NQM111 for different types of CNS cancer
CNS Cancer

GI50 (µM)

SF-268 (Astrocytoma)

0.95

SF-295 (Gliolastoma-Multiforme)

1.05

SF-539

1.35

SNB-19 (Gliblastoma)

1.59

SNB-75 (Astrocytoma)

1.68

U251 (Gliblastoma)

1.27

2.5. Conclusion
In summary, we have successfully developed a convenient and safe
route for the large-scale synthesis of 4,9-dioxo-1,3-dimethylnaphtho[2,3d][1,2,3]triazol-3-ium triflate with significant anticancer activities. This new
method is essential for providing sufficient amount of material for ongoing
anticancer investigations in vivo, which could lead to the development of new
chemotherapeutic agents. This protocol can also be applicable for the
synthesis of other 1,3-dimethyl-1,2,3-triazolium salts of various applications
without the use of potentially explosive methyl azide. Finally, this discovery
can also augment the application of ‘Click’ chemistry that involves the use of
small molecules of organic azide.
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2.6. Experimental Section
General procedure for the preparation of alkyl azides. All the alkyl azides
were prepared following the general procedure mentioned in ref 9.9
General procedure for [3+2] cycloaddition/oxidation: synthesis of
compounds 4a’-c’. To a solution of alkyl azides (estimated 3.2 mmol) in DMF
(10 mL), 1,4-naphthoquinone (1.0 g, 6.4 mmol) was added, and the resulting
solution was heated at 80 ºC for 2 days. After removal of solvent, diethyl ether
(25 mL) was added and the reaction mixture was stirred until the products
precipitated. The precipitated products were collected with Hirsh funnel,
washed with more diethyl ether (25 mL), and dried under vacuum. The yields
were calculated based on the estimated amount of aryl azides used.
General procedure for N-3 alkylation: synthesis of NQM111 and 9. To a
solution of compounds 3a-c (0.35 mmol) in anhydrous toluene (10 mL),
methyl trifluoromethanesulfonate (0.15 mL, 1.40 mol) was added, and the
resulting solution was heated at 100 ºC overnight. After removal of solvent,
diethyl ether (25 mL) was added and the reaction mixture was stirred for 30
min. The precipitated products were collected with Hirsh funnel, washed with
more diethyl ether (25 mL), and dried under the vacuum.
1-[(4-methoxyphenyl)methyl]-1H,4H,9H-naphtho[2,3-d][1,2,3]triazole-4,9dione(4a). This is a known compound10 and was synthesized according to our
general procedures with 81% yield.
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1-benzyl-1H,4H,9H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (4b’).
This is also a known compound5 previously synthesized in our laboratory
according to our general procedures.
1-[(2-methoxyethoxy)methyl]-1H,4H,9H-naphtho[2,3-d][1,2,3]triazole-4,9dione (4c’). This compound was synthesized according to the general
procedures with 59% yield. 1H NMR (300 MHz, CDCl3) δ 8.3 - 8.4 (m, 1H), 8.2
- 8.3 (m, 1H), 7.8 - 7.9 (m, 2H), 6.2 (s, 2H), 3.8 - 3.9 (m, 2H), 3.5 - 3.6 (m,
2H), 3.3 (s, 3H).; 13C NMR (75 MHz, CDCl3) δ 176.8, 175.2, 145.7, 135.4,
134.5, 133.9, 133.4, 128.0, 127.6, 79.1, 71.4, 70.1, 59.2.; ESI/APCI calcd for
C14H14N3O4+ ([MH]+) m/z 288.0984; measured m/z 288.0985.
1-benzyl-3-methyl-4,9-dioxo-1H,4H,9H-naphtho[2,3-d][1,2,3]triazol-3-ium
trifluoromethanesulfonate (9). This is a known compound3 previously
synthesized in our laboratory according to our general procedures.
1,3-dimethyl-4,9-dioxo-1H,4H,9H-naphtho[2,3-d][1,2,3]triazol-3-ium
trifluoromethanesulfonate (NQM111). This is a known compound6 and
synthesized following our new general protocol with 99% yield from 4a and
81% yield from 4c’.
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SYNTHESIS, ANTICANCER STRUCTURE ACTIVITY RELATIONSHIP
INVESTIGATION OF CATIONIC ANTHRAQUINONE ANALOGSa

3.1. Abstract
We have synthesized a series of novel 4,9-dioxo-4,9-dihydro-1Hnaphtho[2,3-d][1,2,3]triazol-3-ium salts, which can be viewed as analogs of
cationic anthraquinones. Unlike the similar analogs that we have reported
previously, these compounds show relatively weak antibacterial activities but
exert strong anticancer activities (low μM to nM GI50), in particular, against
melanoma, colon cancer, non-small cell lung cancer and central nervous
system (CNS) cancer. These compounds are structurally different from their
predecessors by having the aromatic group, instead of alkyl chains, directly
attached to the cationic anthraquinone scaffold. Further investigation of the
structure–activity relationship (SAR) reveals the significant role of electron
donating substituents on the aromatic ring in enhancing the anticancer
activities via resonance effect. Steric hindrance of these groups is
disadvantageous but is less influential than the resonance effect. The
difference in the attached groups at the N-1 position of the cationic
anthraquinone analog is the main structural factor for the switching of
biological activity from antibacterial to anticancer. The discovery of these
compounds may lead to the development of novel cancer chemotherapeutics.
_________________
a
Adapted with permission from [Shrestha, J. P.; Fosso, M. Y.; Bearss, J.;
Chang, C. W.Eur J Med Chem 2014, 77, 96-102.] Copyright 2014. Elsevier
B.V.

3. Introduction

.
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The development of novel antitumor agents has long been the focused
area in cancer chemotherapy.1 Molecules bearing an anthraquinone motif
have attracted great interest due to their potential uses as cancer
chemotherapeutics.2 We have previously reported the synthesis of a library of
cationic anthraquinone analogs, their antibacterial activities, and the mode of
action study.3 Most of these compounds exhibit strong antibacterial activities
against Gram-positive (G+) bacteria with minimum inhibitory concentrations
(MIC's) lower than 1 µg/mL against Staphylococcus aureus (ATCC 25923). By
comparison, two analogs, compounds 9 and NQM11, exert only modest
antibacterial activity with MIC's of 2 and 4-8 µg/mL, respectively (Figure 3.1).
However, these two compounds manifest significant anticancer activities with
GI50 values ranging from low µM to nM in the five-dose 60 cell lines assay
performed by National Cancer Institute (NCI). Further derivatization of
Compound NQM11 will be relatively difficult. In addition, derivatives of
compound 9 having substituents, such as a p-methoxy group on the benzene
ring have been found to be unstable. Therefore, we designed compound 1c to
serve as an analog of NQM111. Our initial goal is to investigate the
importance of methylene group between the cationic anthraquinone scaffold
and the benzene ring.

Figure 3.1. Cationic Anthraquinone Analogs

3.3. Design, Synthesis, and Evaluation of Anticancer Activities
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Using commercially available 1,4-naphthoquinone (1) and phenyl azide
(1A), compound 1c can be synthesized following the protocol reported
previously (Scheme 3.1).4 The first step is a cycloaddition using excess
naphthoquinone followed by an oxidation to yield compound 1b. Methylation
of compound 1b provided compound 1c as a triflate salt, which can be
converted into the corresponding chloride salt after ion-exchange column
chromatography. To our delight, compound 1c displays anticancer activities
comparable to1, which proves that the methylene bridge between the cationic
anthraquinone scaffold and aromatic ring can be omitted. Without the
presence of this methylene group, it is expected that substituents at the ortho
or para positions on the benzene ring of compound 1c will have higher
electronic influence due to the resonance effect. Since ortho-substituents may
cause higher steric hindrance toward the naphthoquinone core, we used
compound 1c as the new lead and synthesized a library of derivatives of
compound 1c with para-monosubstituted benzene rings.

Scheme 3.1. Synthesis of cationic anthraquinone analogs

The synthesis started with the preparation of the corresponding
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diazonium salts from para-substituted anilines, 2a-6a using NaNO2 and HCl
(Scheme 3.2), followed by a nucleophilic aromatic substitution using NaN3 to
obtain the desired para-substituted phenyl azides 2d-6d. Due to their
relatively low boiling points, these aryl azides are used as concentrated
solutions in ether without further purification or complete removal of solvents,
which contribute to the relatively lower yields for the cycloaddition/oxidation
step for the formation of compounds 2b-6b. Meanwhile, we have also
discovered that the counter ion of the cationic anthraquinone analogs has no
effect on the anticancer activities. Thus, these new members were prepared
and tested as trifluoromethanesulfonate (OTf-) salts following the Nmethylation step.

Scheme 3.2. Synthesis of cationic anthraquinone analogs with substituted
aryl groups.

Compounds 3a-e were tested in the single dose 60 cell lines assay
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conducted through the Developmental Therapeutic Program (DTP) of NCI
(Table 3.1). The results of mean cell growth percentages strongly indicate that
the strong electron-donating methoxy group, as in compound 2c, significantly
increases the anticancer activities. Compound 3c is less active than
compound 2c because it has a moderate electron-donating methyl group that
can only provide an inductive effect to increase the electron density on the
benzene ring. Electron-withdrawing groups, such as trifluoromethyl and chloro
groups, further decrease the activities. Interestingly, the fluoro derivative 6c
bearing the most strongly electron-withdrawing group that we have introduced
does not follow this trend. It is possible that smaller steric hindrance of the
fluoro group attributes to the partial restoration of the anticancer activities.

Table 3.1. Single dose 60 cell lines assay of compounds 1c-6c
Compound

Mean cell growth percentagea

1c

-10.18

2c

-24.70

4-methoxyphenyl

3c

11.53

4-methylphenyl

4c

58.69

4-trifluoromethylphenyl

5c

101.70

4-Chlorophenyl

6c

43.38

4-Fluorophenyl

N-1 Substituent
Phenyl

a = Mean cell growth percentage on NCI 60 cell line assay

After confirming the positive role of the strong electron-donating group, we
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decided to further explore the effect of having multiple methoxy groups. The
designs and syntheses of these new members are shown in Scheme 3.3.
Although all the desired aryl azides can be prepared accordingly, the
cycloaddition/oxidation step using aryl azides 10d and 11d offered products
mixed with inseparable by-products. Therefore, only compounds 7a, 8a and
9a were converted to the corresponding cationic anthraquinone analogs 7c,
8c, and 9c, respectively.

Scheme 3.3. Synthesis of cationic anthraquinone analogs with substituted
aryl groups (aryl group substituted with multiple methoxy group).

The results confirm the importance of resonance effect from the
electron-donating methoxy group. For example, the methoxy groups attached
at the meta positions of benzene ring on compound 7c can only increase the
electron density of benzene ring and the cationic anthraquinone scaffold
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through the inductive effect. However, the 3,5-dimethoxy groups increase the
steric hindrance. As a result, the activities of 7c are even lower than 2c. The

methoxy group attached to the para position can increase the electron density
of benzene ring and the cationic anthraquinone scaffold through the
resonance effect. As predicted, both 8c and 9c showed better activities than
7c and even 2c. With less steric hindrance, compound 9c is slightly more
active than compound 8c.
Table 3.2. Single dose 60 cell lines assay of compounds 7c-9c
Compound

Mean cell growth percentage

N-1 Substituent

7c

23.23

3,5-dimethoxyphenyl

8c

-27.06

3,4,5-trimethoxyphenyl

9c

-31.51

3,4-dimethylphenyl

Compounds 1c-4c and 6c-9c were selected to five-dose cell lines
assay also conducted through the DTP of NCI. Overall, these compounds
displayed higher anticancer activities (low µM to nM GI50) against melanoma,
colon cancers, non-small cell lung cancers and central nervous system (CNS)
cancers.5 The GI50 (50% growth inhibition) from the test results are
summarized in Tables 3-6. In general, the activities are consistent with the
results from single dose assay with 1c, 2c and 9c as the most active analogs.
However, slight differences have been noted. For example, based on the
average GI50, 9c is most active against melanoma, non-small cell lung cancer

and CNS cancer followed by either 2c or 1c whereas 1c and 2c are more
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active against colon cancer than 9c.
We have also noticed that certain cell lines appear to be less
susceptible to these cationic anthraquinone analogs. For example, among the
cell lines of melanoma, these compounds are more active against MDA-MB435 than LOX IMVI. A similar tendency has also been found in the anticancer
studies of spongistatin 1.6 Nevertheless, even with the available information
on the mutations of cell lines, it is difficult to provide a satisfactory explanation
for the difference. For instance, SK-MEL-5 that expresses mutant B-Raf
(V600E) and wild-type N-Ras7 is sensitive to the anticancer action of cationic
anthraquinone analogs. A similar cell line, SK-MEL-28 that also expresses
mutant B-Raf (V600E) and wild-type N-Ras7 is much less susceptible to these
compounds.

3.4. Discussion of Anticancer and Antibacterial SAR
We are currently in the process of investigating the possible anticancer
mode of action and the potential cellular targets of these cationic
anthraquinone analogs. Based on the structure-activity relationship (SAR) that
has been revealed, we believe that electron density via the resonance effect
and steric hindrance of the N-1 aryl groups play important roles in the
anticancer activities. From the mean cell growth percentage and average GI50
values, a general tendency that indicates the presence of electron- donating
substituents at the N-1 aryl group, enhance the anticancer activity when the
tested compounds are arranged in order of decreasing electron density
(Figures 3.2 and 3.3). Further analysis shows that only the groups that can

increase the electron density via the resonance effect can also enhance the
anticancer activity. As mentioned previously, both compounds 7c and 3c,
which contain electron-donating groups but cannot increase the electron
density via the resonance effect, are less active than 1c, which has no
substituent attached. This observation suggests the adverse steric effect in
anticancer activity.

Figure 3.2. Comparison of mean cell growth percentage

Figure 3.3. Comparison of average GI50 (nM)
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We have reported the synthesis and antibacterial activity of a library of
cationic anthraquinone analogs bearing two alkyl groups at the N-1 and N-3
positions (Figure 3.4).3b, 4 One of the lead compounds, NQM1083a which is
similar to compound NQM111 but has an octyl group instead of a methyl
group at the N-1 position, exerts only poor anticancer activities (mean cell
growth percentage = 44.8%, Table 3.11). These results are consistent with
the negative effect of steric hindrance on the anticancer activities.

Figure 3.4. Dialkyled cationic anthraquinone analogs

When comparing the SAR of anticancer and antibacterial activities
(Table 3.11), we conclude that a small alkyl chain (CH3, entry 11, NQM111) or
aromatic ring at the N-1 position increases the anticancer activities. A longer
alkyl chain is crucial for antibacterial activities but not the anticancer activities
(octyl, entry 12, NQM108).3a, 3b Overall, reduced steric hindrance and
increased electron density via resonance are crucial for tuning the biological
activity of cationic anthraquinone analogs from being antibacterial to
anticancer and vice versa. Although we are investigating the possible modes
of anticancer activity and targets, we have noted that NQM111 also has a
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similar profile of anticancer activities: particularly active against melanoma,
colon cancer, non-small cell lung cancer, and CNS cancer.8 This interesting
finding implies that the cationic anthraquinone is the structural motif
responsible for the anticancer activity and that the N-1 substituent plays an
auxiliary role. It also points to two possible modes of action: intercalation of
nucleic acids and disruption of cellular redox processes. The former is favored
by small steric hindrance as in the case of NQM111, and the latter can be
affected by the electronic property (redox potential) of the compounds.
Finally, for compounds with substituted benzene rings at N-1 position,
we have summarized the SAR as following: 1) a methylene group between
the benzene and triazole moieties is not needed 2) electron-donating
substituents at the para position of the benzene ring increase the anticancer
activities, and 3) reduced steric hindrance is beneficial for anticancer
activities.
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Table 3.11. Comparison of antibacterial and anticancer activities

a

MIC against S.

Mean cell growth

aureusa (µg/mL)

percentage (%)

Entry

Compound

1

1c

8

-10.18

2

2c

4-8

-24.70

3

3c

4

11.53

4

4c

ND

58.69

5

5c

ND

101.70

6

6c

ND

43.38

7

7c

16

23.23

8

8c

32

-27.06

9

9c

4

-31.51

10

9

4-8

-37.9

11

NQM111

2

-46.0

12

NQM108

0.032

44.8

Staphylococcus aureus (ATCC 25923)

3.5. Conclusion
In conclusion, we have developed a concise synthesis of cationic
anthraquinone analogs bearing aryl substituents. The simplicity in the
synthesis can enable a scale-up production when needed and greatly
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increase the chance of developing practical therapeutics. Investigation of the
SAR also reveals the structural factors for tuning the biological activities
(anticancer vs. antibacterial) of these compounds. These discoveries may
lead to the development of novel anticancer therapeutics. It will also help to
the development of antibacterial agents with less cytotoxicity.

3.6. Experimental Section
General procedure for the preparation of aryl azides. To a solution of
substituted anilines (46.7 mmol) in water (50 mL), conc. HCl (11.2 mL, 37%
v/v) was added. The reaction mixture was cooled to 0˚C and NaNO2 (46.7
mol) dissolved in 10 mL water was added. After being stirred for 10 min.,
NaN3 (60.0 mmol) was added portion wise. The mixture was stirred for 1.5 h
at r.t. Formation of an oily compound was observed. The mixture was
extracted with ether (3 x 25 mL), and then the ether extracts were washed
with water (2 x 50 mL) and once with brine (50 mL). The organic layer was
dried over anhydrous MgSO4 or Na2SO4, filtered and concentrated to about
1/10 of the original volume. The resulting aryl azides were used without
further purification.
General procedure for [3+2] cycloaddition/oxidation: synthesis of
compounds 1b-9b. To a solution of aryl azides (estimated 3.2 mmol) in DMF
(10 mL), 1,4-naphthoquinone (1.0 g, 6.3 mmol) was added, and the resulting
solution was heated at 60˚C for 2 days. After removal of the solvent, diethyl
ether (25 mL) was added and the reaction mixture was stirred until the
products precipitated. The precipitated products were collected with a Hirsh
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funnel, washed with more diethyl ether (25 mL), and dried under vacuum. The
yields were calculated based on the estimated amount of aryl azides used.
1-Phenyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (1b). This is a known
compound9 and was synthesized according to our general procedures for the
preparation of aryl azides and [3+2] cycloaddition/oxidation with 27% yield. 1H
NMR (300 MHz, CDCl3) δ 8.4 (m, 1H), 8.2 (m, 1H), 7.8 - 7.9 (m, 2H), 7.7 - 7.8
(m, 2H), 7.6 -7.7 (m, 3H). 13C NMR (100 MHz, CDCl3) δ 177.2, 174.5, 146.2,
135.5, 135.4, 134.7, 133.6, 133.4, 133.3, 131.1, 129.5 (2C), 128.0, 127.9,
125.3 (2C).
1-(4-Methoxyphenyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (2b). This
is a known compound10 was synthesized according to our general procedures
for the preparation of aryl azides and [3+2] cycloaddition/oxidation with 33%
yield.
1-p-Tolyl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (3b). This compound
was synthesized according to the general procedures for the preparation of
aryl azides and [3+2] cycloaddition/oxidation with 45% yield. 1H NMR (300
MHz, CDCl3) δ 8.38 (dd, J = 7.5, 1.4 Hz, 1H), 8.21 (dd, J = 7.4, 1.4 Hz, 1H),
7.84 (m, 2H), 7.61 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 8.2 Hz, 2H), 2.50 (s, 3H);
13

C NMR (75 MHz, CDCl3) δ 177.1, 174.4, 145.6, 141.4, 135.2, 134.6, 133.4,

133.3, 133.2, 132.9, 129.9 (2C), 127.8, 127.7, 124.9 (2C), 21.5; ESI/APCI
calcd for C17H11N3O2+ ([MH]+) m/z 290.0924; measured m/z 290.0931.
1-(4-Trifluoromethylphenyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
(4b). This compound was synthesized according to the general procedures for
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the preparation of aryl azides and [3+2] cycloaddition/oxidation with 30%
yield. 1H NMR (300 MHz, CDCl3) δ 8.4 (m, 1H), 8.2 (m, 1H), 7.8 - 8.0 (m, 6H);
13

C NMR (100 MHz, CDCl3) δ 176.5, 174.5, 146.0, 133.8, 133.0, 133.7, 135.6,

134.9, 133.2, 128.1, 127.9, 126.7 (2C), 125.7 (2C); ESI/APCI calcd for
C17H9F3N3O2+ ([MH]+) m/z 344.0641; measured m/z 344.0643.
1-(4-Chlorophenyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (5b). This
compound was synthesized according to the general procedures for the
preparation of aryl azides and [3+2] cycloaddition/oxidation with 32% yield. 1H
NMR (300 MHz, CDCl3) δ 8.37 (dd, J = 7.6, 1.7 Hz, 1H), 8.21 (dd, J = 7.6, 1.7
Hz, 1H), 7.83 (dq, J = 7.6, 1.7 Hz, 2H), 7.6 - 7.7 (m ,2H), 7.5 - 7.6 (m, 2H); 13C
NMR (75 MHz, CDCl3) δ 176.9, 174.9, 146.1, 137.1, 135.4, 134.8, 134.7,
133.8, 133.4, 133.1, 133.1, 129.6 (2C), 127.9, 127.7, 126.4 (2C); ESI/APCI
calcd for C16H9ClN3O2+ ([MH]+) m/z 310.0378; measured m/z 310.0381.
1-(4-Fluorophenyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (6b). This
compound was synthesized according to the general procedures for the
preparation of aryl azides and [3+2] cycloaddition/oxidation with 30% yield. 1H
NMR (300 MHz, CDCl3) δ 8.38 (dd, J = 7.6, 1.7 Hz, 1H), 8.21 (dd, J = 7.5, 1.4
Hz, 1H), 7.8 - 7.9 (m, 2H), 7.7 - 7.8 (m, 2H), 7.3 (m, 2H); 13C NMR (100 MHz,
CDCl3) δ 177.1, 174.5, 163.9 (d, JC-F = 251 Hz), 146.1, 135.5, 134.8, 133.8,
133.5, 133.2 (2C), 131.5, 128.0, 127.9, 127.4 (d, JC-F = 9 Hz, 2C), 116.6 (d, JCF=

23.5 Hz, 2C). ESI/APCI calcd for C16H9FN3O2+ ([MH]+) m/z 394.0673;

measured m/z 294.0678.

79

1-(3,5-Dimethoxyphenyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (7b).
This compound was synthesized according to the general procedures for the
preparation of aryl azides and [3+2] cycloaddition/oxidation with 41% yield. 1H
NMR (3200 MHz, CDCl3) δ 8.37 (d, J = 7.3 Hz, 1H), 8.22 (d, J = 8.2 Hz, 1H),
7.8 – 7.9 (m, 2H), 6.88 (d, J = 1.9 Hz, 2H), 6.6 – 6.7 (m, 1H), 3.87 (s, 6H); 13C
NMR (100 MHz, CDCl3) δ 177.2, 174.3, 161.2, 146.1, 136.8, 135.3, 134.7,
133.5 (3C), 127.9, 103.7, 103.1, 56.0 (2C); ESI/APCI calcd for C18H14N3O4+
([MH]+) m/z 336.0979; measured m/z 336.0971.
1-(3,4,5-Trimethoxyphenyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
(8b). This compound was synthesized according to the general procedures for
the preparation of aryl azides and [3+2] cycloaddition/oxidation with 43%
yield. 1H NMR (300 MHz, CDCl3) δ 8.7 (dd, J = 1.7, 7.2 Hz, 1H), 8.04 (dd, J =
1.7, 6.8,1H), 7.8 – 7.9 (m, 2H), 7.01 (s, 2H), 3.97 (s, 3H), 3.95 (s, 6H); 13C
NMR (75 MHz, CDCl3) δ 177.1, 174.3, 153.4 (2C), 145.9, 139.9, 135.3, 134.6,
133.3, 133.0, 130.7, 127.8 (2C), 102.8 (2C), 61.2, 56.6; ESI/APCI calcd for
C19H16N3O5+ ([MH]+) m/z 366.1084; measured m/z 366.1084.
1-(3,4-Dimethoxyphenyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione (9b).
This compound was synthesized according to the general procedures for the
preparation of aryl azides and [3+2] cycloaddition/oxidation with 45% yield. 1H
NMR (300 MHz, CDCl3) δ 8.6 (d, J = 7.2 Hz, 1H), 8.21 (d, J = 7.6 Hz, 1H), 7.8
(m, 2H), 7.32 (d, J = 8.6 Hz, 2H), 7.03 (d, J = 8.6 Hz, 1H), 3.99 (s, 3H), 3.96
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 177.1, 174.4, 150.9, 149.2, 145.9, 135.2,
134.5, 133.3, 133.1, 128.2, 127.8 (3C), 117.7, 110.7, 108.6, 56.4, 56.3;
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ESI/APCI calcd for C18H14N3O4+ ([MH]+) m/z 336.0979; measured m/z
336.098.
General procedure for N-3 alkylation: synthesis of compounds 1c-9c.
To a solution of compounds 1b-9b (0.35 mmol) in anhydrous toluene (10 mL),
methyl trifluoromethanesulfonate (0.15 mL, 1.38 mol) was added, and the
resulting solution was heated at 100˚C overnight. After removal of the solvent,
diethyl ether (25 mL) was added and the reaction mixture was stirred for 30
min. The precipitated products were collected with a Hirsh funnel, washed
with more diethyl ether (25 mL), and dried under the vacuum.
4,9-Dioxo-3-methyl-1-phenylnaphtho[2,3-d][1,2,3]triazol-3-ium chloride
(1c). This compound was synthesized according to the general procedure for
N-3 alkylation with 74% yield. 1H NMR (300 MHz, CD3OD) δ 8.4 (m, 1H), 8.3
(m, 1H), 7.9 - 8.1 (m, 4H), 7.8 - 7.9 (m, 1H), 7.7 - 7.8(m, 2H), 4.83 (s, 3H); 13C
NMR (75 MHz, CD3OD) δ 172.7, 171.0, 136.2, 136.1, 135.9, 138.8, 133.9,
133.1, 132.8, 132.3, 129.6 (2C), 128.0, 127.7, 125.8 (2C), 40.3; ESI/APCI
calcd for C17H12N3O2+ ([M]+) m/z 290.0924; measured m/z 290.0924.
4,9-Dioxo-1-(4-methoxyphenyl)-3-methylnaphtho[2,3-d][1,2,3]triazol-3ium trifluoromethanesulfonate (2c). This compound was synthesized
according to the general procedure for N-3 alkylation with 80% yield. 1H NMR
(300 MHz, CD3OD) δ 8.4 (m, 1H), 8.3 (m,1H), 8.0 - 8.1 (m, 2H), 7.8 - 7.9 (m,
2H), 7.2 - 7.3 (m, 2H), 4.81(s, 3H), 3.98(s, 3H); 13C NMR (100 MHz, CD3OD)
δ 172.9, 171.1, 163.4, 136.2 (2C), 135.9, 135.6, 133.2, 132.3, 128.1, 127.7,
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127.2 (2C), 126.3, 114.7 (2C), 55.4, 40.2; ESI/APCI calcd for C18H14N3O3+
([M]+) m/z 320.1030;
4,9-Dioxo-3-methyl-1-p-tolyl-naphtho[2,3-d][1,2,3]triazol-3-ium
trifluoromethanesulfonate (3c). This compound was synthesized according
to the general procedure for N-3 alkylation with 79% yield. 1H NMR (300 MHz,
CD3OD) δ 8.4 (m, 1H), 8.3 (m, 1H), 8.0 (m, 21H), 7.76 (d, J = 8.5 Hz, 2H),
7.57 (d, J = 8.2 Hz, 2H), 4.81 (s, 3H), 2.54 (s, 3H); 13C NMR (75 MHz,
CD3OD) δ 172.8, 171.0, 144.1, 136.1, 135.8, 133.6, 131.9, 130.6 (2C), 130.1,
127.9, 127.6, 125.2, 121.2, 65.6, 40.0, 20.1, 14.1; ESI/APCI calcd for
C18H14N3O2+ ([M]+) m/z 304.1081; measured m/z 304.1081.
4,9-Dioxo-3-methyl-1-(4-trifluoromethylphenyl)naphtho[2,3d][1,2,3]triazol-3-ium trifluoromethanesulfonate (4c). This compound was
synthesized according to the general procedure for N-3 alkylation with 90%
yield. 1H NMR (300 MHz, CD3OD) δ 8.3 (m, 1H), 8.1 – 8.2 (m, 1H), 7.8 - 8.0
(m, 6H), 4.67 (s, 3H); 13C NMR (100 MHz, CD3OD) δ 172.6, 171.1, 136.6,
136.3, 136.2, 132.9, 132.3, 128.2, 127.9, 127.1 (2C), 126.9, 40.5; ESI/APCI
calcd for C18H11F3N3O2+ ([M]+) m/z 358.0798; measured m/z 358.0788.
1-(4-Chlorophenyl)-4,9-dioxo-3-methylnaphtho[2,3-d][1,2,3] triazol-3-ium
trifluoromethanesulfonate (5c). This compound was synthesized according
to the general procedure for N-3 alkylation with 99% yield. 1H NMR (300 MHz,
CD3OD) δ 8.1 - 8.2 (m, 1H), 7.9 (m, 2H), 7.7 - 7.9 (m, 3H), 7.7 (m, 2H), 4.76
(s, 3H). 13C NMR (75 MHz, CH3OD) δ 172.5, 170.9, 139.2, 136.2, 135.9,
135.8, 132.9, 132.2 (2C), 129.9 (2C), 128.0, 127.7, 127.2 (2C), 40.3;
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ESI/APCI calcd for C17H11ClN3O2+ ([M]+) m/z 324.0534; measured m/z
324.0544.
1-(4-Fluorophenyl)-4,9-dioxo-3-methylnaphtho[2,3-d][1,2,3]triazol-3-ium
trifluoromethanesulfonate (6c). This compound was synthesized according
to the general procedure for N-3 alkylation with 69% yield. 1H NMR (300 MHz,
CD3OD) δ 8.4 (m, 1H), 8.3 (m, 1H), 8.0 - 8.1 (m, 2H), 7.9 - 8.0 (m, 2H). 7.9 8.0 (m, 2H), 7.5 (m, 2H), 4.80 (s, 3H); 13C NMR (100 MHz, CD3OD) δ 171.2,
169.7, 163.7 (d, JC-F = 252 Hz), 134.7(2C), 134.5 (2C), 131.5, 128.4, 127.0 (d,
JC-F = 9 Hz, 2C), 126.6, 126.3, 115.3, (d, JC-F = 24.1 Hz, 2C), 38.8. ESI/APCI
calcd for C17H11FN3O2+ ([M]+) m/z 308.0832; measured m/z 308.0838.
1-(3,5-Dimethoxyphenyl)-4,9-dioxo-3-methylnaphtho[2,3-d][1,2,3]triazol3-ium trifluoromethanesulfonate (7c). This compound was synthesized
according to the general procedures for N-3 alkylation with 95% yield. 1H
NMR (300 MHz, CD3OD) δ 8.3-8.4 (m, 1H), 8.04 (m, 1H), 8.0 (m, 2H), 7.04 (d,
J = 2.4 Hz, 2H), 6.91 (t, J = 2.0 Hz, 1H), 4.81 (s, 3H), 3.88 (s, 6H); 13C NMR
(75 MHz, DMSO-d6) δ 173.3, 171.4, 161.4 (2C), 137.1, 136.7, 135.9, 135.0,
133.4, 132.1, 128.5, 128.2, 104.7 (2C), 56.7 (2C), 40.3; ESI/APCI calcd for
C19H16N3O4+ ([M]+) m/z 350.1135; measured m/z 350.1137.
4,9-Dioxo-3-methyl-1-(3,4,5-trimethoxyphenyl)naphtho[2,3d][1,2,3]triazol-3-ium trifluoromethanesulfonate (8c). This compound was
synthesized according to the general procedure for N-3 alkylation with 99%
yield. 1H NMR (300 MHz, DMSO-d6) δ 8.4 (m, 1H), 8.3 (m, 1H), 8.0 (m, 2H),
7.19 (s, 2H), 4.7-4.8 (m, 3H), 3.88 (s, 9H); 13C NMR (75 MHz, DMSO-d6) δ
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173.4, 171.5, 153.7, 148.4 (2C), 139.9, 137.0, 136.6, 135.9, 133.4, 132.2,
128.6, 128.1, 124.2, 104.1 (2C), 60.9, 57.1 (2C), 40.3. ESI/APCI calcd for
C20H18N3O5+ ([M]+) m/z 380.1241; measured m/z 380.1231.
1-(3,4-Dimethoxyphenyl)-4,9-dioxo-3-methylnaphtho[2,3-d][1,2,3]triazol3-ium trifluoromethanesulfonate (9c). This compound was synthesized
according to the general procedure for N-3 alkylation with 94% yield. 1H NMR
(300 MHz, DMSO-d6) δ 8.3 (m,1H), 8.2 (m,1H), 8.0 – 8.1 (m, 2H), 7.56 (s,
1H), 7.50 (dd, J = 2.0, 8.6 Hz, 1H), 7.33 (d, J = 8.6 Hz, 1H), 4.75 (s, 3H), 3.90
(s, 3H), 3.80 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 173.4, 171.5, 152.5,
149.4, 137.0, 136.6, 136.1, 136.0, 133.4, 132.2, 128.5, 128.2, 123.2, 118.9,
112.1, 109.5, 56.7, 56.6, 41.7. ESI/APCI calcd for C19H16N3O4+ ([M]+)
m/350.1135; measured m/z 350.1129.
Procedure for MIC determination
A solution of selected bacteria (S. aureus) was inoculated in the
Trypticase Soy broth at 35ºC for 1 - 2 h, after which the bacterial
concentration was found and diluted with broth, if necessary, to an absorption
value of 0.08 to 0.1 at 625 nm. The adjusted inoculated medium (100 µL) was
diluted with 10 mL of broth, and then applied to a 96-well microtiter plate (50
µL). A series of solutions (50 µL each in 2-fold dilution) of the tested
compounds was added to the testing wells. The 96-well plate was incubated
at 35 ºC for 12 - 18 h. The minimum inhibitory concentration (MIC) is defined
as the minimum concentration of compound needed to inhibit the growth of
bacteria. The MIC results are repeated at least three times.
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CHAPTER 4
A MODE OF ACTION STUDY OF CATIONIC ANTHRAQUINONE ANALOGS: A
NEW CLASS OF HIGHLY POTENT ANTICANCER AGENTSa

4.1. Abstract
Previously we reported the synthesis and structure-activity relationship
(SAR) study of a series of novel 4,9-dioxo-4,9-dihydro-1H-naphtho[2,3d][1,2,3]triazol-3-ium salts, which had very potent anti-proliferative activities (low
µM to nM GI50) against a broad range of cancer cells. These compounds, which
can be viewed as cationic anthraquinone analogs (CAA's), are selective against
cancer cells over bacteria or fungi as compared to the antibacterial CAA's that
have also been reported by our group. Herein, we report the mode of action
study of CAA's, which reveals at these compounds trigger apoptosis by
generating extensive reactive oxygen species (ROS). The generation of
extensive ROS species causes oxidative stress, a decrease in mitochondrial
membrane potential, depletion of glutathione (GSH), and release of caspase-3;
which ultimately kills cancer cells by programmed apoptosis. Furthermore, we
have also showed that CAA's have an activity of 8-fold higher against A549 cell
over the non-cancerous MRC-5 cell.
_________________
a
Adapted with permission from [Shrestha, J. P.; Subedi, Y. P.; Chen, L.; Chang,
C.-W. T. MedChemComm 2015, 6 (11), 2012-2022.Copyright 2014. The Royal
Society of Chemistry.
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4.2. Introduction
The development of novel antitumor agents has long been a focused area
in cancer chemotherapy.1 Molecules bearing quinone motifs have attracted great
interest due to their potential uses as cancer chemotherapeutics. 2 Several
anticancer drugs containing quinone motifs, e.g. daunomycin, doxorubicin,
mitomycin C, and mitoxantrone (Figure 4.1, A), have been approved by the U.S.
Food and Drug Administration (FDA) for clinical use. Natural compounds
containing quinone motifs, such as cribrostatin, streptonigrin, and β-lapachone,
are further being studied for their anti-cancer activities,3 of which streptonigrin
and β-lapachone are already being used as experimental drugs. Our laboratory is
dedicated to synthesizing small molecules containing 1,4-naphthoquinone or
other heterocyclic motifs as antimicrobial or anticancer drugs. These compounds
can be prepared in 2–3 steps from an inexpensive starting material (1,4naphthoquinone), and the synthetic protocol can be scaled up for large quantities
(5–10 g) without the requirement of cumbersome purification, such as column
chromatography. Furthermore, various anionic counter ions of these compounds
can be conveniently exchanged to improve the bioavailability. Previously, we
have reported the syntheses of two different sets of CAAs that possess
predominantly either antibacterial activities or anticancer activities.4 The first set
of compounds (Fig. 4.1,B, left) exhibits strong antibacterial activity against Grampositive (G+) bacteria with minimum inhibitory concentrations (MICs) lower than 1
μg mL−1 against Staphylococcus aureus (ATCC 25923). The second set of
compounds (Figure 4.1, B, right) exhibits strong anti-cancer activity with GI50
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values ranging from low μM to nM in the five-dose 60-cell line assay performed
by the National Cancer Institute (NCI). By comparison, the first set of compounds
only possesses strong antibacterial activity and weak anti-cancer activity,
whereas the second set of compounds exhibits strong anticancer activity and
weak antibacterial activity. The syntheses and SAR studies have already been
reported for both sets of compounds.4 The SAR study has revealed that an 8carbon alkyl chain at the 3-N position is the optimum chain length for antibacterial
activity, whereas the electron donating group with low steric hindrance at the 3-N
aryl group is the best group for anticancer activity. More SAR study details are
presented in Figure 4.1, B; and a mode of action study for the first set of
antibacterial compounds have already been reported.5 Herein, we wish to report
the possible modes of action for the second set of compounds that possess
anticancer activity.

Figure 4.1. (A) FDA-approved anticancer drugs containing quinone motifs; (B)
Cationic 1,4-naphthoquinone analogs from our laboratory
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Scheme 4.1. Summary of Synthesis of anticancer cationic anthraquinone
analogs

Several studies have shown that redox cycling properties of quinone are
responsible for their anti-cancer activities.3, 6 One-electron reduction of quinone
forms a semiquinone radical and two-electron reduction of quinone forms
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dihydroquinone. Both the semiquinone radical and the dihydroquinone can be reoxidized back to their parent quinone by molecular oxygen forming ROS in a
redox cycle.7 The superoxide anions formed during the redox cycle are known to
cleave DNA, peptides, and proteins.8 Once cells are unable to repair these
damages, apoptosis is triggered. The redox cycle can be facilitated by cellular
reductases, electron leakage from mitochondria, or another hydroquinone. 9 Our
mode of action studies focuses on the quantification of cationic 1,4naphthoquinone analogs that induced ROS, oxidative stress, mitochondrial
membrane potential, glutathione (GSH) and caspase-3, all of which are related to
programmed apoptosis.

4.3. Results and discussion
4.3.1. Cell viability analysis
All the compounds (1c–9c) were tested against NCI-60 cell lines, and their
GI50 and LC50 values were reported in our earlier publication.4c For the purpose of
the mode of action study, here we chose to study the growth-inhibitory effect of
compound 2c on the human lung alveolar epithelial cancer cell line (A549) and
lung fibroblast cell line (MRC-5) as the control. Various doses of compound 2c
were added to cells for 48 h of incubation, and the curve of cell growth was
determined by means of a 3-(4,5-methylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. The IC50 (4.2 μM) value obtained under our experimental
conditions is much higher than the GI50 (0.34 μM) value determined by the NCI.
The growth medium used in our experiment (DMEM 1×) has a higher level of
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glutathione than the medium used by the NCI (RPMI), and the higher level of
glutathione is believed to be responsible for the observed higher IC50 value.
Similarly, the IC50 value obtained for etoposide is 3.9 μM (Table 4.1) for the
A549 cell line under similar conditions and was found to be at least 4 fold higher
than the reported GI50 (0.99 μM) value from the NCI. As shown in Figure 4.2,
compound 2c exhibits a strong cytotoxic effect on the A549 cell line and
moderate cytotoxic effects on the MRC-5 cell line. The selectivity is at least 8 fold
higher for the A549 cell line vs. the MRC-5 cell line. This selective cytotoxic effect
on the assayed cancer cell line greatly enhances the potential of these CAAs as
chemotherapeutic agents. As a control experiment, we also tested the anticancer
activity of antibacterial compound NQM108 on A549 under similar conditions as
2c. The compound showed very low cytotoxicity with an IC50 value of 83.33 μM.

Table 4.1. IC50 values for compound 2c, etoposide, and NQM108
Cell line

IC50 2c

IC50 Etoposide

IC50 NQM108

A549

4.2 ± 0.5

3.9

83 ± 15

MCR-5

35 ± 9.0

-

-

Figure 4.2. 2c, NQM108, and etoposide dose-response curves
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4.3.2. Compound 2c does not affect the cell cycle
Many anticancer compounds arrest cells in a certain phase of a cell cycle,
for instance, cisplatin arrests cells in the G2 phase,10 doxorubicin arrests cells in
the G2/M phase,11 camptothecin arrests cells in the G2 phase12 and some
anticancer compounds do not arrest cells at all.13 The cell cycle arrest provides
some mechanistic information on the mode of action, which makes this assay
very important. The cell cycle analysis was carried out after incubation with
different concentrations of compound 2c over 24 h. The cells were then analyzed
by flow cytometry. The cell cycle analysis showed no significant effect on any
stages of the cell cycle (Figure 4.4), and the percentage of cells in each phase of
the cell cycle was not affected by drug concentration. This result also indicates
that the mode of action of CAAs is not related to growth and/or growth regulating
factors. These compounds are also unlikely to be topoisomerase inhibitors
because all the reported topoisomerase inhibitors (e.g., doxorubicin and
camptothecin) are known to arrest the cell cycle at a certain phase. For example,
cribrostatin 6 does not affect the cell cycle and does not inhibit topoisomerase.
Even though compounds arresting the cell cycle are desirable for a specific
target, they are not very useful for targeting quiescent cells mostly present in the
tumor.
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Figure 4.3. Cell cycle analysis for A549 cells incubated with 2c for 24 h (A & B)

4.3.3. Compound 2c induces apoptosis in cancer cells
FITC annexin-V (A)/propidium iodide (PI) double staining assay was
utilized to study the mode of cell death. The assay takes advantage of the
earliest apoptotic process, when phosphatidylserines (PS) from the inner side of
the plasma membrane translocate to the outer surface.14 FITC annexin V is a
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fluorochrome dye conjugated with Ca2+ dependent phospholipid-binding protein
with a higher affinity for PS. This high affinity for FITC annexin-V allows detection
of early apoptotic cells.14 Once the integrity of the cell membrane is
compromised, the PI can get inside the cell and bind with DNA. The level of PI
intake directly correlates with the severity of membrane damage. The cells were
treated with various concentrations of 2c (0.0, 0.01, 0.10, 1.0, 10.0, and 100.0
μM) over 24 h and then analyzed by flow cytometry for the cells stained with
annexin-V and PI (Figure 4.5). Three distinctive populations of apoptotic cells
(gate P12, A+/PI−; gate 13, A+/PI+; and gate P14, A+ /PI++; Figure 4.5) were
observed. The total number of apoptotic cells increased from 7.70% to 8.74%,
11.06%, 11.07%, 35.44%, and 61.28% at 0.00 μM, 0.01 μM, 0.1 μM, 1.0 μM, 10
μM, and 100 μM concentrations of 2c, respectively. The progression of the
apoptosis started from healthy cells (A− /PI−) to early apoptosis (A+/PI−) followed
by late apoptosis (A+/PI+) and finally necrosis (A+/PI++). This process is a very
clear indication of cell death via apoptosis. The progression trend of the
apoptosis cycle can be observed in the bar diagram (Figure 4.5, B). The general
morphological characteristics of apoptosis such as cell shrinkage, nuclear
condensation, and mitochondrial membrane damage can be observed in Figure
4.6.
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Figure 4.4. Annexin-V/PI assay for apoptosis (A and B),* = P ≤ 0.05, and **** = P
≤ 0.0001
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Figure 4.5. (A) Morphological changes in A549 cells treated with 2c; (B)
morphological changes in the A549 cell nucleus and mitochondria treated with 2c
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4.3.4. Compound 2c induces oxidative stress by ROS generation
It is well documented that due to rapid metabolic processes, a level of
endogenous ROS is elevated in cancer cells compared to normal healthy cells. 15
Further elevation of the exogenous ROS pushes oxidatively stressed cancer cells
over a critical redox threshold triggering apoptosis.16 Quinone motif-containing
compounds (e.g., adaphostin, menadione, daunorubicin, and doxorubicin) are
known to kill cancer cells by further elevating the ROS level. Selective killing of
cancer cells over healthy cells is possible through this pathway by increasing the
amount of ROS that pushes cancer cells over their critical threshold, while
normal cell lines can survive this ROS level.16-17 The level of ROS production in
A549 cells was determined by using a dichloro-dihydro-fluorescein diacetate
(DCFH-DA) dye. The non-fluorescent DCFH-DA dye is cleaved by cellular
esterase in the cell which upon oxidation forms a highly fluorescent adducts. The
cells were then analyzed by flow cytometry for any increase in the fluorescence
intensity. The incubation of 2c for 4 h showed a correlation between the
concentration of compound 2c and the ROS level (Figure 4.6). The incubation of
2c at 10 nM and 100 nM showed no effect on ROS production, whereas the
incubation of 2c at 10 μM and 100 μM showed a significant increase in mean
fluorescence. Antibacterial compound NQM108 (Figure 1B, left) was also tested
for ROS under similar conditions. It also generated ROS, but the level of ROS
was much lower than that of ROS produced by 2c (Figure 4.6, C). The level of
ROS at control was considered 100%. At 10 μM and 100 μM, NQM108 only
increased mean fluorescence by ~108% and ~177%, whereas 2c produced over
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133% and 226%, respectively. It is likely that cells can cope with the lower level
of ROS generated by NQM108, whereas ROS generated by 2c exceeds the
critical threshold resulting in apoptosis.

Figure 4.6. Reactive oxygen production in A549 after incubation of 2c (A and B),
and NQM108 (C) for 4 h. * = P ≤ 0.05; ** = P ≤ 0.01, and **** = P ≤ 0.0001
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4.3.5. Compound 2c depletes glutathione in cancer cells
Glutathione (GHS) is a natural antioxidant in many cells. GHS neutralizes
harmful ROS produced in the cells. Although the majority of GHS is present in
the cytosol, a small percentage of GHS exists in the mitochondria and is critical
for cellular functions. Cellular redox processes that take place in the mitochondria
are vulnerable to the detrimental effect of ROS, and depletion of mitochondrial
GHS can have catastrophic consequences. For instance, it has been reported
that GHS depletion can serve as a potent activator of apoptosis signaling. 18 The
depletion of GHS was measured using a glutathione fluorometric assay kit
(Biovision, USA). A549 cells were incubated with 2c for 48 h, and the samples
were analyzed in a 96-well plate with excitation at 360 nm and emission
detection at 460 nm. The level of GHS was expressed as 100% for the control,
and the decrease in GHS levels after drug treatment was compared to the control
(Figure 4.7). Concentration-dependent GHS depletion was observed. Although
incubation of 2c at 0.1 μM only decreased the GHS level to 99.35%, significant
GHS depletion was noted at 1 μM and higher concentrations of 2c with the GHS
level at 88.76%, 23.87%, and 12.13% after incubation at 1 μM, 10 μM, and 100
μM 2c, respectively. This result from the GHS depletion assay also supports our
earlier results from the ROS assay as GHS depletion elevates ROS level in the
cells and vice versa.
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Figure 4.7. Glutathione depletion at different time intervals. ** = P ≤ 0.01,
and **** = P ≤ 0.0001

4.3.6. Compound 2c decreases mitochondrial membrane potential
Mitochondria play a key role in activating apoptosis. A decrease in
mitochondrial membrane potential (ΔΨm) during apoptosis has been well
reported.16 Therefore, we decided to examine the effect of 2c on ΔΨm. A
decrease in ΔΨm leads to matrix condensation and exposure of cytochrome c to
the intermembrane space, facilitating the release of cytochrome c into the
cytoplasm. This process is facilitated by the oligomerization of effectors
BAK/BAX which forms pores in the mitochondrial membrane.19 The release of
cytochrome c from the mitochondria promotes the activation of the executioner
protein caspase cascade. We incubated different concentrations of 2c with A549
cells for 24 h. We used Rhodamine 123 for the ΔΨm analysis, which distributes
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electrophoretically into the mitochondrial matrix according to the electric potential
distribution across the inner mitochondrial membrane.20 The intensity of
Rhodamine 123 was analyzed by flow cytometry. The experiment showed a
concentration-dependent change in ΔΨm even at a very low concentration (10
nM) of 2c. The gate P4 (Figure 4.8, A and B) represents the percentage of cells
with decreased ΔΨm. The percentage of cells with decreased ΔΨm increased
from 1.7% (control) to ~2.55% in 10 nM and 100 nM of 2c. Significant changes
were only observed from 1 μM to 100 μM 2c. Overall, the percentage of cells
which showed a decrease in ΔΨm increased to 4.10%, 51.40%, and 88.05% at 1
μM, 10 μM, and 100 μM 2c, respectively. Under similar conditions, NQM108 only
increased the percentage of cells to 25% at 10 μM and 50% at 100 μM (Figure
4.8, C and D) with a decrease in ΔΨm. These data correlate with our earlier ROS
results where NQM108 produced a lower amount of ROS than 2c. A lower
amount of ROS damages a lower number of mitochondria resulting in less cell
death. The correlation of these two results clearly explains why 2c is active and
NQM108 is not against cancer.
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Figure 4.8. Decrease in mitochondrial membrane potential in A549 cells at
different concentrations of 2c (A and B). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and
****P ≤ 0.0001
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Figure 4.9. Decrease in mitochondrial membrane potential in A549 cells at
different concentrations of NQM108 (C and D). *P ≤ 0.05, **P ≤ 0.01, ***P ≤
0.001, and ****P ≤ 0.0001
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4.3.7. Caspase-3 release assay
The release of the caspase family of protein is a well-known biomarker for
apoptosis via the mitochondrial pathway. The release of mitochondrial
cytochrome c into the cytoplasm activates initiator caspase-8/9. Once activated,
they cleave and activate downstream effector caspase-3/-7.21 Caspase-9
activates executioner caspase-3 and caspase-7. They are the executioner
proteins which upon activation cleave major cellular components. Caspase-3 is
the key player in the digestion of the cellular component, while caspase-7 is
responsible for the detachment of apoptotic cells.22 Therefore, identification of
caspase-3 release is the key final step in the identification of the mode of action
through this pathway. Different concentrations of 2c (0.01 μM, 0.1 μM, 1.0 μM,
10.0 μM and 100 μM) were incubated with A549 cells for 4 h, 12 h, 24 h, and 48
h. The release of caspase-3 was detected by using a caspase-3 fluorometric
assay kit (BioVision, USA) and analyzed by a 96- well plate reader. The result
showed an increase in caspase-3 activity in a concentration and time-dependent
manner (Figure 4.10, A and B). The highest level of caspase-3 activity was
observed when compound 2c (0.01 μM and 0.1 μM) was incubated with A549 for
24 h. The caspase-3 level had already decreased to the base level at 10.0 μM.
Time-dependent release of caspase-3 was also observed at 0.1 μM drug
concentration at 4 h, 12 h, and 48 h. The release of the caspase family of
proteins is a biomarker for mitochondrial-dependent apoptosis; hence, the
increased activities of caspase-3 in our experiment support the hypothesis that
CAA generates apoptosis via the mitochondrial pathway.
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Figure 4.10. (A) Caspase-3 release at different time intervals (1 h, 4 h, 12 h and
48 h); (B) caspase-3 release at different concentrations (0 μM, 0.01 μM, 0.1 μM,
1.0 μM, and 10.0 μM). * = P ≤ 0.05, and ** = P ≤ 0.01
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4.3.8. Due to their structural similarities and redox properties, CAAs are expected
to form toxic ROS by hijacking the function of ubiquinone (Q) in the mitochondrial
electron transport chain
Having identified ROS generation as the key mechanism, it is crucial to
identify the source of ROS. It is well known that ROS are generated by the
reduction of molecular oxygen by semiquinone radicals. Semiquinone radicals
are formed by one-electron reduction of a quinone. The process of formation of a
semiquinone radical most likely takes place in the mitochondria, where they can
hijack the function of electron transporter Q in the electron transport chain. It is
well documented that diverse cationic dyes can readily penetrate the outer
membrane of the mitochondria and accumulate in the inner mitochondrial
membrane electrophoretically.20a, 23 The cationic nature of CAAs may facilitate
this accumulation.20a, 23 Once accumulated in the membrane, CAAs can interfere
with the function of ubiquinone due to the similarities in their structure and redox
properties. The proposed mechanism is also supported by our previous work
where we reported that antibacterial CAAs exert antibacterial activity by inhibiting
the redox processes of bacteria.5 A direct correlation has been reported on the
reduction potential and cytotoxicity of multiple heterocyclic quinones.24
The redox potentials of CAAs were determined by cyclic voltammetry
(Table 4.2). All these compounds can undergo redox reactions similar to the
inter-conversion of quinones, semiquinone radicals, and dihydroquinones via
one-electron or two-electron process (Scheme 4.2). All of the compounds tested
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exhibited two reversible electrochemical reductions in tetrabutylammonium
hexafluorophosphate (TBAF) buffer in anhydrous acetonitrile.

Scheme 4.2. Process of formation of semi-quinone and hydroquinone

We observed that all the active compounds have first E1/2 higher than
−160 mV, and the less active or inactive compounds have first E 1/2 lower than
−160 mV. The most active compounds with the lowest percentage mean cell
growth have greater than −180 mV first E1/2. The active compounds contain
electron donating groups while the inactive compounds contain electron
withdrawing groups. The reduction potential of ubiquinone is approximately −556
mV vs. Ag/AgCl, −602 vs. SCE in an aprotic solvent.25 Since the redox potentials
of CAAs are much lower than Q, they are much better electron acceptors
compared to Q. Thus, it is quite possible that CAAs can replace Q and receive
electrons directly from electron-transporting complex (ETC) I or II forming
semiquinone radicals (SQRs). It has been reported that SQRs can readily reduce
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molecular oxygen leading to the formation of ROS. Based on this information, a
proposed mechanism is outlined in Scheme 4.3.

Scheme 4.3. Proposed mechanism of ROS formation in ETS by cationic
anthraquinone analogs

The electron withdrawing groups on CAAs can better stabilize the SQRs
and slow down the formation of ROS from the reduction of molecular oxygen,
whereas electron donating groups on CAAs can destabilize the SQRs and
facilitate the electron transfer to molecular oxygen forming ROS. Although both
classes of CAAs can generate ROS, those compounds containing electron
donating groups generate ROS more rapidly and contribute to their higher
cytotoxicity. Previously published research also supports this claim where the
substitution with electron withdrawing groups on quinone decreases the rate of
formation of superoxide, while substitution of electron donating groups increases
the rate of formation of superoxide.26 Since we only observed a direct correlation
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between the first half wave reduction potentials (E1/2) and anticancer activity, it is
likely that these compounds work by one-electron reduction at the cellular level
rather than a two-electron reduction process, and the redox process between the
anthraquinone and semiquinone radicals is responsible for the anticancer activity
of CAAs.

Table 4.2. Comparison of redox potentials with antibacterial and anticancer
activities.
Compound

First wave E1/2

Second wave E1/2

Mean cell growth

(mV) vs (Ag/AgCl,

(mV) vs (Ag/AgCl,

percentage (%) in

3M NaCl)

3M NaCl)

NCI-60 cell line assay

1c

-163.5

-866.5

-10.18

2c

-182.5

-885.0

-24.70

4c

-176.0

-881.5

11.53

5c

-130.5

-823.5

58.69

3c

-148.5

-842.5

101.70

6c

-156.5

-886.0

43.38

8c

-168.0

-867.0

23.23

7c

-182.5

-762.0

-27.06

9c

-182.0

-885.5

-31.51

Ubiquinone

-567 25

-

-
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Table 4.3. Summary of cyclic voltammetry

4.4.8. DNA alkylation experiment
Mitomycin C, a quinone motif bearing anticancer drug is known to alkylate
nucleic acid after bio-reductive activation. These cationic 1,4-naphthoquinone
analogs may also function as alkylating agents (methylation) via the N-3 methyl
group. The alkylation experiment was carried out with guanosine monophosphate (GMP). GMP was ion exchange with cyclohexylamine to increase its
solubility in methanol. The mixture of 2c and GMP were incubated at 37 ºC and
analyzed by 1 H NMR at different time intervals (Figure 4.6). It is expected that
the methylation of GMP will result in the appearance of new methyl peak; and a
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change in the chemical shift of anomeric proton. The loss of methyl from 2c will
result in the formation of new compound 2b, which has a very different pattern in
the 1H NMR chemical shift. No shift in anomeric proton and no appearance of
new signals in 1H NMR demonstrate that they are not an alkylating agent.

4.3.9. DNA cleavage experiment
Numerous studies have reported that compounds bearing quinone motif
are capable of causing photo-induced, transition metal complex-assisted, or
oxidative DNA cleavage. We selected compound 1c for the initial DNA cleavage
study using supercoiled pUC 19 DNA, which has been commonly used in DNA
cleavage studies. The experiments were conducted using Tris buffer (pH 8). To
our surprise, compound 1c manifests a concentration-dependent DNA cleavage
without the presence of transition metal complex, light irradiation or oxidative
reagent (Figure 4.11, top). One dominant form of nicked supercoiled DNA (form
II) was noted with concentrations of 1c at 240 and 480 M while no or very little
DNA cleavage at the lower tested concentrations (15 and 60 M). We then tested
the remaining compounds at 240 M, and all the cationic 1,4-naphthoquinone
analogs were capable of cleaving DNA (Figure 4.11). However, there is no
obvious correlation between the anticancer activities and the extent of DNA
cleavage. For example, compound 2c has similar anticancer activity as 1c but
cause much less DNA cleavage as compared to compound 1c. The lack of
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correlation and DNA cleavage only at much higher concentration than IC50 can
be attributed to the possibility that the direct DNA damage may not be the
primary mode of its anticancer activity. However, this property is unique to these
cationic 1,4-naphthoquinone analogs and is different from other reported classes
of DNA-cleaving agents.

Figure 4.11. DNA cleavage experiment with different concentration of 1c (Top);
DNA cleavage experiment for other CAAs at 240 M concentration (Bottom)
4.4. Conclusion
We have identified the anticancer mode of action of cationic
anthraquinone analogs. This mode of action study has revealed that these
compounds generate ROS and deplete the natural antioxidant glutathione in the
cell. These active compounds possibly hijack the function of ubiquinone due to
their similarities in structure and redox properties, thus generating semiquinone
radicals. The semiquinone radicals, in turn, reduce molecular oxygen to form
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highly reactive ROS. The generation of extensive ROS and the depletion of the
level of glutathione lead to oxidative stress and damage to the mitochondrial
membrane lowering its membrane potential. The programmed apoptosis is
caspase dependent and triggered by the release of caspase-3. To
unambiguously identify the mode of action, we have performed. We have
observed direct DNA cleaving capability of these compounds at a higher
concentration. Although the DNA cleaving properties of CAAs without light and
transition metals are unique to these specific compounds, the DNA cleavage was
only observed at a much higher concentration than the IC50 value and, therefore,
may not be attributed as the primary mode of action. Other experiments
conducted in our laboratory have also ruled out the possibility that CAAs can
function as alkylating agents. In summary, our results have confirmed the
anticancer mode of action for this novel CAAs and may pave the way for the
development of new chemotherapeutic agents.

4.5. Experimental Section
Proton nuclear magnetic resonance spectra were recorded using JOEL
300 OR Bruker ascend 500 spectrometers. Chemical shifts were reported as
parts per million (ppm) downfield from tetramethylsilane in δ unit and coupling
constants were given in cycles per seconds (Hz). Signal multiplicities were
indicated by s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet). 13C
NMR spectra were obtained using JOEL 300 at 75 MHz or Bruker ascend 500 at
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125 MHz. Routine 13C NMR spectra were fully decoupled by broad-band WALTZ
decoupling. All NMR spectra were at ambient temperature. Atmospheric pressure
chemical ionization (APCI) or electron spray ionization (ESI) was provided by the
mass spectrometry facilities, University of California, Riverside. Flow cytometry
analysis was carried out using BD Biosciences Special Order FACS Aria™ II and
the service was provided by Center for Integrated Biosystems (CIB), Utah State
University.
Chemical reagents and chromatography solvents were purchased from
Aldrich Chemical Co. or Acros Chemical Co. and were used without further
purification unless otherwise noted. Dichloromethane was freshly distilled from
calcium hydride under a nitrogen atmosphere. Pyridine and triethylamine were
stored over 4 Å molecular sieves. Column chromatographic purifications were
carried out on silica gel 230x450 mesh, Sorbent Tech. Analytical TLC was
performed on Sorbent Technologies silica gel glass TLC plates. Visualization
was accomplished with UV light (254 nm).

General Procedure for Cell Culture. A549 and MRC-5 cells were grown
in commercial DMEM 1X (Gibco) with 10% fetal bovine serum (FBS, Gibco), 100
U/mL penicillin, and 100 μg/mL streptomycin at 37 °C and 5% CO2. The cells
were allowed to adhere for 48 h before drug treatment.

General Procedure for Cell Viability Assay. The cells were seeded in
96-well microtiter plates (3000/200 μL). After 48 h of incubation in the
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corresponding media, cells were treated with various concentrations of test
compounds (0.0, 0.01, 0.10, 1.0, 10.0, and 100.0 µM) for 48 h. 20 μL of MTT
stock solution (5 mg/mL) was added to each well and incubated for 4 h at 37 °C.
Upon completion of incubation, the media was carefully removed and washed
twice with 100 mL of pbs buffer. Then, 100 μL of DMSO was added to each well;
agitated on an orbital shaker for 15 min., and the absorbance at 590 nm with 620
nm filter was determined with a microplate reader. The results were expressed
as viability compared with that of control. The experiment was carried out in
triplicate in three independent experiments.

General Procedure for Cell Cycle Analysis. A549 cells (5x104 cells/2
mL) were cultured in 6-well plates and allowed to adhere for 48 h. Different
concentrations of test compounds (0.0, 0.01, 0.10, 1.0, 10.0, and 100.0 µM) were
added and incubated for 24 h. The adherent cells were removed by 0.25%
Trypsin/EDTA solution and harvested by centrifugation (1200 rpm at 4 °C) for 5
min. The cells were washed with 1 mL of PBS buffer and collected by
centrifugation. The pelleted cells were then re-suspended in 0.3 mL of PBS
buffer, fixed with 0.7 mL of ice-cold ethanol and left at 4 °C for overnight. The
cells were then centrifuged and collected, washed with PBS buffer and recentrifuged. The pelleted cells were then re-suspended in 0.25 mL of PBS buffer
and 5µL of 10 mg/mL RNase A was added. The solution was incubated at 37 °C
for 1 h. 10 µL of 1 mg/mL PI solution was added and left in the dark for FACS
analysis (488nm).

116

General Procedure for Annexin-V/PI Apoptosis Assay. A549 cells
(5x104 cells/2mL) were cultured in 6- well plates and allowed to adhere for 48 h.
Different concentrations of test compound (0.0, 0.01, 0.10, 1.0, 10.0, and 100.0
µM) were added and incubated for 24 h. The adherent cells were removed by
0.25% Trypsin-EDTA solution and harvested by centrifugation (1200 rpm at 4 °C)
for 5 min. The cells were washed with 1 mL of PBS buffer and collected by
centrifugation. The cell pellet was re-suspended in 500 µL of 1X binding buffer
(Annexin V/PI assay kit, Biovision, USA.); 5 µL of annexin V-PI was added and
incubated at room temperature for 5 min in the dark. The cells were then
analyzed by flow cytometry at ex. 488 nm and em. 578nm.

General Procedure for ROS Measurement Assay. A549 cells (5x104
cells/2 mL) were cultured in 6-well plates and allowed to adhere for 48 h. 2 mL
solution of DCFH-DA (10 µM) in serum free media was added and incubated for
1 h. The cells were washed with 1 mL of PBS buffer and different concentrations
of test compound (0.0, 0.01, 0.10, 1.0, 10.0, and 100.0 µM) in normal media were
added and incubated for 4 h. The adherent cells were removed by 0.25%
Trypsin-EDTA solution and harvested by centrifugation (1200 rpm at 4 °C) for 5
min. The pelleted cells were washed once with 1 mL of PBS buffer and
centrifuged. The cell pellets were then diluted with 500 µL of PBS buffer and
analyzed in FACS scan at Ex/Em: ~ 492 – 495/517 – 527 nm.
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General Procedure for Mitochondrial Membrane Potential
Measurement. A549 cells (5x104 cells/2 mL) were cultured in 6-well plates and
allowed to adhere for 48 h. Different concentratins of test compound (0.0, 0.01,
0.10, 1.0, 10.0, and 100.0 µM) were added and incubated for 24 h. 100 mg/mL
rhodamine 123 stock solution was directly added to the culture media and
incubated at 37 °C for 30 min. The adherent cells were removed by 0.25%
Trypsin-EDTA solution and harvested by centrifugation (1200 rpm at 4 °C) for 5
min. The pelleted cells were washed twice with 1 mL of PBS buffer and
centrifuged. The cell pellets were then diluted with 500 µL of PBS buffer analyzed
in FACS scan.

General Procedure for Glutathione Depletion Assay. A549 cells (5x104
cells/2ml) were cultured in 6-well plates and allowed to adhere for 48 h. Different
concentrations of test compound (0.0, 0.01, 0.10, 1.0, 10.0, and 100.0 µM) were
added and incubated for 48 h. The adherent cells were removed by 0.25%
Trypsin-EDTA solution and harvested by centrifugation (1200 rpm at 4 °C) for 5
min. The level of glutathione was measured with modified Glutathione
Fluorometric assay kit (Biovision, catalog number: K51-100). Fluorescence
intensities were measured using 96 well plate readers (BioTek Synergy H4
reader with Gen5 software) with 360 nm excitation and 461 nm emission.

General Procedure for Caspase-3 Release Assay. A549 cells (1x106
cells/2 mL) were cultured in 6-well plates and allowed to adhere for 48 h.
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Different concentrations of test compound (0.0, 0.01, 0.10, 1.0, 10.0, and 100.0
µM) were added and incubated for 4, 12 h and 48 h . The adherent cells were
removed by 0.25% Trypsin-EDTA and harvested by centrifugation (1200 rpm at
4 °C) for 5 min. The level of Caspase-3/CPP32 was measured with Caspase3/CPP32 fluorometric assay kit (Biovision, catalog number: K105-25).
Fluorescence intensities were measured using 96 well plate reader (BioTek
Synergy H4 reader with Gen5) with 400 nm excitation and 505 nm emission.

General Procedure for Fluorescence Imaging. Following the same
procedure as cell viability, cells are seeded in µ-Slide 8 well plate (CVRGLS
LABKITKII 8 Well#1.5). The morphological studies in cells were studied in phase
contrast mode while nuclear condensation (DAPI nuclear stain) and
mitochondrial morphology (Rhodamine 123) were studied by fluorescence
microscopy (Olympus IX70). The images were recorded by spot RT color camera
(model: 2.2.1) and processed with spot 5 software.

General Procedure for Cyclic Voltammetry Measurement. Cyclic
Voltammetry was performed in a BASi-Epsilon EC system using 0.1 M
Tetrabutylammonium hexafluorophosphate (TBAF) for electrochemical analysis
(purity ≥99.0 %) in an anhydrous Acetonitrile as a supporting electrolyte. The 3
mm glassy carbon electrode was used as the working electrode, together with a
platinum counter-electrode and an Ag/AgCl reference electrode. The working
electrode was polished with 0.05 μM alumina, washed with dH2O, and sonicated
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for 5 min. before using for each sample. 2 mM samples in supporting electrolyte
were prepared just before the electrochemical experiment, degassed with N 2 for
15 min., and readings were taking under an N2 blanket.

General Procedure for Statistical data analysis. All results are
presented as the mean ± standard deviation of three independent experiments
using GraphPad Prism software using an unpaired t-test. The results were
considered significant at P < 0.05 (* = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001;
and **** = P ≤ 0.0001).

General Procedure for DNA Cleaving Experiment. The DNA cleavage
experiments of supercoiled pUC19 plasmid DNA 0.75 μL (~125 ng) by 1c (15,
30, 60, 120, 240, and 480 μM) containing ~3% DMSO in (10mM Tris-HCl, 1mM
EDTA Buffer and 50mM NaCl) buffer at pH 8.0 were performed by agarose gel
electrophoresis (Fisher Biotech Electrophoresis FB-SB-170 System). The
samples were incubated for 24 h at 37 °C in the dark. A 3.3 μL loading dye
containing 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol , 30% (v/v)
glycerol was added and electrophoresis was carried out at 65 V for 55 min in
Tris–Acetate–EDTA (TAE) buffer (40 mM Tris-acetate and 1 mM EDTA) using
1% agarose gel containing 0.5 µg/mL ethidium bromide. The gels were viewed in
an Alpha Innotech Corporation Gel doc system at 302 nm and photographed
using an 8 MP Olympus digital camera. Following the same condition,
electrophoresis was carried for rest of the compounds at 240 μM concentrations.
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CHAPTER 5
SYNTHESIS AND BIOORGANIC INVESTIGATION OF QUINONE BASED
MULTI-CATIONIC TRIAZOLIUM AMPHIPHILES

5.1. Abstract
In search of broad spectrum synthetic antimicrobials, we have developed
a series of synthetic 1,1'-(hexane-1,6-diyl)bis(3-alkyl-4,9-dioxo-4,9-dihydro-1Hnaphtho[2,3-d][1,2,3]triazol-3-ium) salts, which have very potent antimicrobial
activity against a broad range of susceptible and resistant species of fungi and
bacteria. These compounds possess azole, quinone, and quaternary ammonium
complex (QAC). Quinone moieties can act as a redox inhibitor in bacteria while
multi-cationic head with alkyl chain can disrupt membrane integrity. The in vitro
biological evaluation has already shown that they are very active against a series
of fungal and bacterial strains. The cytotoxicity assay in SKOV-3, a cancer cell
line, has already demonstrated that they are selectively toxic to fungi and
bacteria over human cells.
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5.2. INTRODUCTION
Amphiphilic molecules have attracted greater interest as antifungal or
antibacterial agents for many years. Recently, many studies on aminoglycosides
based amphiphilic molecules have been published.1 The protonated amines on
an aminoglycoside form a cationic head and together with a long alkyl chain form
an amphiphilic molecule. Amphiphilic molecules based on quaternary ammonium
salts (QAC) have been known for many years, and it is one of the most common
antimicrobial agents used as disinfectants.2 They are widely used in domestic,
industrial, agricultural and clinical applications.3 Several different types of QACs
either possessing mono- or multi-cationic functional groups can be obtained in
the market. Several studies have shown that bacteria can not develop resistance
against multi-cationic QACs but can develop resistance against mono-cationic
QAC easily. Due to the strong positively charged cationic head and long lipophilic
tail, this compound acts as an amphiphilic molecule similar to the phospholipids
found in the cell membrane. Disruption of the phospholipid bilayer to compromise
cell membrane is the primary mode of action.4
Our laboratory is dedicated to synthesizing cationic amphiphiles based on
aminoglycoside or 1,4-naphthoquionone moiety. We have already published
several QAC types of compounds and their mode of action.5 These compounds
are antimicrobial when substituted with an alkyl chain,5 but anticancer when
substituted with the aromatic ring.6 These antimicrobial cationic anthraquinone
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Figure 5.1. Cationic amphiphiles
analogs (CAAs) act as a redox inhibitor at minimum inhibitory concentration
(MIC) and act as a membrane disrupter at higher concentrations.7 The anticancer
CAAs act as ROS-generating molecules.8
In this article, we are presenting a small multi-cationic QAC type of
molecule (MCAAs) which consists of redox active cationic anthraquinone head
and an alkyl lipophilic tail. The redox-active quinone head is connected with alkyl
chain via triazole moiety. Alkylation at triazole gives it cationic property, and the
positive charge generated by alkylation is delocalized around triazole ring. The
molecule is a hybrid in nature as it is the combination of several popular
antimicrobial scaffolds, such as quinone, triazole, and QAC. All MCAAs are
active against a broad range of resistant fungi and bacteria with low cytotoxicity
against human cell lines. Synthesis, biological evaluation, and mode of action
study are discussed here.
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Figure 5.2. Structural comparison of CAAs from our laboratory
5.3. Result and Discussion
5.3.1 Design and Chemical Synthesis
Conferring multiple cationic functional groups and multiple alkyl chains in a
single molecule was our primary focus while designing these compounds. For the
ease of synthesis, the bridging alkyl chain connecting two cationic quinone heads
was kept constant (6 carbon chain) to form NQM123, and the rest of the analogs
were derivatized from it. The free alkyl chain lengths were varied from C1 to C10.
Beyond C10, we observed solubility issues in water for biological testing. So, no
derivatives with carbon chain longer than C10 were synthesized. The compounds
can be synthesized from a very cheap starting material, 1,4-naphthoquinone, and
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do not require cumbersome purification via column chromatography. Therefore, a
large quantity can be synthesized easily.
The SN2 reaction of 1,6-dibromohexane dissolved in DMF with sodium
azide at room temperature resulted into a 1,6-diazidohexane (2). The compound
was directly used for the next step without further purification. NQ123 could be
synthesized by 1,3 dipolar cycloaddition using excess 1,4-naphthoquinone
followed by oxidation (82% yield). NQ123 was methylated with methyl triflate to
give NQM123C1. For the synthesis of NQM123C2-NQM123C10, first, the
hydroxyl group on corresponding alkyl alcohol was converted to leaving group via
triflic anhydride to form corresponding alkyl triflate. The alkyl triflates were directly
used for alkylation to form corresponding compound NQM123C2-NQM123C10.
All the compounds were characterized by 1H NMR, 13C NMR, and high-resolution
mass spectrometry. HPLC analysis determined the purity level of all the final
compounds and found >95% pure.
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Scheme 5.1. Synthesis of multi-cationic CAAs
5.3.2. Antibacterial Activity
All the newly synthesized compounds were tested for antibacterial and
antifungal activity. No biological activity was observed for intermediate compound
NQ123 at 5 mg/mL, which emphasizes the importance of cationic property and
alkylation. All the final compounds (NQM123C1-NQM123C10) exhibited strong
activity against Staphylococcus aureus (ATCC25923). NQM123C1-NQM123C4
are the most active compounds against S. aureus with MIC 0.125 µg/mL. MIC
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decreased by 32-64 fold for S. aureus and the chain length of free alkyl chain at
N3 increased to 6 or more. The trend was observed in reverse order for MRSA
(ATCC 33591) and E.coli (ATCC25922). In both cases, MICs for NQM123C6NQM123C10 are >250 µg/mL, but they become active with a longer chain. It is
evident from this data that shorter MCAAs are more active against S. aureus
while MCAAs with longer alkyl chain are more active against MRSA and E. coli. It
is very likely that these compounds have a different mode of action when
substituted with shorter or longer chain. Therefore, we observed a different trend
in antibacterial activity. From our earlier publication on the similar compounds
with a shorter alkyl chain, we showed that these compounds interfere with
bacterial redox process at MIC level, and also act as a membrane disrupter at
higher concentration level.7
5.3.3. Antifungal Activity
Azoles and QAC’s are also known to have potent antifungal activity. Azole-based drugs,
such as fluconazole, posaconazole, and itraconazole are considered first of the line of
treatment for candidiasis caused by the yeast that belongs to the genus Candida. As a
matter of fact, our new analogs possess both azole moiety and QAC property. This
hybrid compound may have superior antifungal activity, which prompted us to explore
their in vitro antifungal activity. The compounds were tested against major human
pathogenic fungi. This fungi test includes Aspergillus, Candida, Cryptococcus, and
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Table 5.1. Antibacterial activity of MCAAs (µg/mL)
G+ Bacteria
Compound

G- Bacteria

S. aureus
(ATCC25923)
MIC (µg/mL)

MRSA (ATCC33591)
MIC (µg/mL)

E. coli
(ATCC25922)
MIC (µg/mL)

NQM123C1

0.125

>250

>250

NQM123C2

0.125

>250

>250

NQM123C4

0.125

>250

>250

NQM123C6

4

8-16

8-16

NQM123C8

4

4-8

2-4

NQM123 C10

8

4-8

4-8

Vancomycin

1

2-4

64-125

Kanamycin A

2-4

-

4

Rhodotorula species. The MIC values of NQM123C1 -NQM123C10, K20,
and fluconazole against various fungi is summarized in Table 5.2. NQM123C1NQM123C6 did not exhibit any antifungal activity against Aspergillus flavus,
Candida albicans 64124, and Candida albicans MYA2876. However, they
exhibited mild to moderate antifungal activity against Cryptococcus neoformans
and Rhodotorula pilimanae with MIC values ranging from 125 µg/mL and 62.5-
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15.6 µg/mL, respectively. Both NQM123C8 and NQM123C10 exhibited excellent
antifungal activity for all the tested fungal species. The MIC values ranging from
15.63 to 7.81 µg/mL, 3.91 µg/mL, 3.91 µg/mL, 3.91-2.0 µg/mL, and 2.0 µg/mL for
Aspergillus flavus, Candida albicans 64124, Candida albicans MYA2876,
Cryptococcus neoformans, and Rhodotorula pilimanae, respectively.
NQM123C10 is the most active compound with a slight edge over NQM123C8,
the MIC values for Aspergillus flavus and Cryptococcus neoformans decreased
to half for NQM123C10. The result showed that antifungul activity depended on
free alkyl chain length where said activity exhibited free alkyl chain lengths that
were longer than 6. Aspergillus species are one of the most emerging causes of
invasive aspergillosis in immunocompromised individuals, and Aspergillus flavus
is one of the leading cause of the reduction in crop yield. Similarly, Candida
albicans are one of the most prevalent fungal pathogens. The results are very
significant as both NQM123C8 and NQM123C10 are active against Aspergillus
species and azole-resistant Candida albicans.

5.3.4. Fungal Mechanism of Action
Disruption of the cell membrane is the primary mode of action for antimicrobial
amphiphiles including aminoglycoside amphiphiles and QAC amphiphiles. The
effect of our most active antifungal candidate, NQM123C10, was used to observe
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its effect on the fungal membrane. Sytox Green, a dye that gives off fluorescence
upon penetrating membrane-compromised cells and binding to nucleic acid, was
used to investigate the cell membrane disruption. The study was performed on
Candida albicans ATCC 64124 and filamentous fungi, Fusarium graminearum
B4-A5. The fungi were exposed to NQM123C10 at MIC level for 1 h. The result
was as expected and the compound functioned as a membrane disrupter in both
fungi (Figure 5.3 and 5.4).

Table 5.2. Antifungal activity of MCAAs (µg/mL)
Compound

Aspergillus Candida
albicans
flavus
64124

Candida
albicans

Cryptococcus Rhodotorula
neoformans

pilimanae

MYA2876
NQM123C1

>250

>250

>250

125

62.5

NQM123C2

>250

>250

>250

-

-

NQM123C4

>250

250

>250

-

-

NQM123C6

>250

250

>250

125

15.6

NQM123C8

15.63

3.91

3.91

3.9

2.0

NQM123C10

7.81

3.91

3.91

2.0

2.0

K20

7.8

31.3

15.6

7.8

-

>250

1.56

-

-

Fluconazole
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Bright field

Fluorescent

Merge

Figure 5.3. Candida albicans, control (top). Candida albicans incubated with
NQM123C10 for 1h (bottom).
Bright field

Fluorescent

Merge

Figure 5.4. Fusarium graminerium single hypha experiment Control (top).
Incubated with NQM123C10 for 1h (bottom).
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5.3.5. Cytotoxicity
A cytotoxicity assay was carried out against a human ovary cancer cell, SKOV3
to evaluate the cytotoxicity of our new compounds. This assay is critical as it
determines how selectively these compounds kill desired pathogens over human
cells. The results are shown in Figure 5.5. At a concentration of 10 µg/mL,
NQM123C1 displayed mild toxicity while other derivatives displayed no toxicity.
All the MIC values for antifungal activity are lower than 10 µg/mL except
NQM123C8 MIC for Aspergillus flavus. The most active compounds NQM123C8
and NQM123C10 showed the least toxicity to SKOV3.

NQM123C1
NQM123C2
NQM123C4
NQM123C6
NQM123C8
NQM123C10

120

Relative cell viability

100

80

60

40

20

0

Control

0.1
1.0
100
10
Concentration of drugs (µg/mL)

Triton 1X

Figure 5.5. Cytotoxicity assay for all MCAA analogs
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5.4. Conclusions and Significance
In conclusion, we successfully synthesized a new series of QAC type of
antimicrobial agent. Compounds substituted with shorter alkyl chain were very
active against S. aureus while compounds substituted with longer alkyl chain
were active against E.Coli and MRSA. For compounds with alkyl chain longer
than 6, they showed excellent antifungal activity against a broad range of fungal
species, including resistant species. The cytotoxicity assay showed little to no
cytotoxicity against a human cell line.

5.5. Experimental Section
General procedure for the preparation of alkyl azides. All the alkyl
azides were prepared as previously reproted.
General procedure for [3+2] cycloaddition/oxidation: synthesis of
compounds NQ123C1-NQM123C10. To a solution of alkyl azides (estimated
3.2 mmol) in DMF (10 mL), 1,4-naphthoquinone (2.0 g, 12.8 mmol) was added,
and the resulting solution was heated at 80 ˚C for two days. After removal of
solvent, diethyl ether (25 mL) was added and the reaction mixture was stirred
until the products precipitated. The precipitated products were collected with
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Hirsh funnel, washed with more diethyl ether (25 mL), and dried under vacuum.
The yields were calculated based on the estimated amount of alkyl azides used.
General procedure for N-3 alkylation: synthesis of NQM123C1.

To

a solution of compounds NQ123C1 (0.35 mmol) in anhydrous toluene (10 mL),
methyl trifluoromethanesulfonate (0.30 mL, 2.80 mol) was added, and the
resulting solution was heated at 100 ˚C overnight. After removal of solvent,
diethyl ether (25 mL) was added and the reaction mixture was stirred for 30 min.
The precipitated products were collected with Hirsh funnel, washed with more
diethyl ether (25 mL), and dried under the vacuum.
General procedure for N-3 alkylation: synthesis of NQM123C2NQM123C10. The alcohol (4 equiv) and pyridine (8 equiv) were dissolved in
anhydrous toluene (10 mL) and cooled in an ice−water bath before Tf2O (8 equiv)
was slowly added. The mixture was stirred at 0 °C for 2 h. The reaction mixture
was passed through a sodium sulfate filter. The sodium sulfate filter cake was
further washed with another 10 mL of anhydrous toluene. The toluene fractions
were combined, and NQM123C2-NQMC10 (0.11 g, 1 equiv) was then added.
This mixture was then refluxed at 110 °C for overnight. After removal of solvent,
diethyl ether (25 mL) was added and the reaction mixture was stirred for 30 min.
The precipitated products were collected with Hirsh funnel, washed with more
diethyl ether (25 mL), and dried under the vacuum.
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1,1'-(hexane-1,6-diyl)bis(1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione)
(NQ123). This compound was synthesized according to the general procedures
with 84 % yield. 1H NMR (300 MHz, CDCl3) δ 8.3 - 8.4 (m, 1H), 8.2 - 8.3 (m, 1H),
7.8 - 7.9 (m, 2H), 6.2 (s, 2H), 3.8 - 3.9 (m, 2H), 3.5 - 3.6 (m, 2H), 3.3 (s, 3H).; 13C
NMR (75 MHz, CDCl3) δ 176.8, 175.2, 145.7, 135.4, 134.5, 133.9, 133.4, 128.0,
127.6, 79.1, 71.4, 70.1, 59.2.; ESI/APCI calcd for C14H14N3O4+ ([M]++) m/z
325.1784; measured m/z 325.1773.
1,1'-(hexane-1,6-diyl)bis(3-methyl-4,9-dioxo-4,9-dihydro-1Hnaphtho[2,3-d][1,2,3]triazol-3-ium) triflate (NQ123C1). This compound was
synthesized according to the general procedures with 84 % yield. 1H NMR (300
MHz, CD3OD) δ 8.4 - 8.3 (m, 2H), 8.1 - 8.0 (m, 2H), 5.1 (t, J = 6.9 Hz, 2H), 2.1 1.9 (m, 2H), 4.7 (s, 3H), 2.2 - 2.1 (m, 2H), 1.5 - 1.5 (m, 2H); 13C NMR (125 MHz,
DMSO - D6) δ 173.9 (2H), 137.7, 137.6, 136.9, 136.8, 133.5 (2C), 129.1, 129.0,
54.9, 50.1, 29.4, 25.9, 15.1; ESI/APCI calcd for C30H30N6O4++ ([M]++) m/z
269.1159; measured m/z 269.1146.
1,1'-(hexane-1,6-diyl)bis(3-ethyl-4,9-dioxo-4,9-dihydro-1Hnaphtho[2,3d][1,2,3]triazol-3-ium) triflate (NQ123C2). This compound was
synthesized according to the general procedures with 84 % yield. 1H NMR (300
MHz, DMSO - D6) δ 8.4 - 8.2 (m, 2H), 8.1 - 8.0 (m, 2H), 5.0 - 5.1 (m, 4H), 2.1 1.9 (m, 2H), 1.60 (t, J = 7.2 Hz, 2H), 1.5 1.4 (m, 2H); 13C NMR (125 MHz, DMSO
- D6) δ 173.9 (2H), 137.7, 137.6, 136.9, 136.8, 133.5 (2C), 129.1, 129.0, 54.9,
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50.1, 29.4, 25.9, 15.1; ESI/APCI calcd for C30H30N6O4++ ([M]++) m/z 269.1159;
measured m/z 269.1146.
1,1'-(hexane-1,6-diyl)bis(3-butyl-4,9-dioxo-4,9-dihydro-1Hnaphtho[2,3-d][1,2,3]triazol-3-ium) triflate (NQM123C4). This compound was
synthesized according to the general procedures with 84 % yield. 1H NMR (300
MHz, DMSO) δ 8.4 - 8.2 (m, 2H), 8.1 - 8.0 (m, 2H), 5.0 - 5.1 (m, 4H), 2.1 - 1.9 (m,
4H), 1.5 - 1.3 (m, 4H), 0.90 (t, J = 7.6 Hz, 3H); 13C NMR (125 MHz, DMSO) δ
172.6, 172.5, 135.9, 135.8, 135.7 (2C), 132.6, 132.5, 127.7, 127.6, 54.1, 53.9,
30.4, 28.2, 25.1, 19.1, 12.2; ESI/APCI calcd for C34H38N6O4++ ([M]++) m/z
297.1472; measured m/z 297.1462.
1,1'-(hexane-1,6-diyl)bis(3-hexyl-4,9-dioxo-4,9-dihydro-1Hnaphtho[2,3-d][1,2,3]triazol-3-ium) triflate (NQM123C6). This compound was
synthesized according to the general procedures with 84 % yield. 1H NMR (300
MHz, DMSO) δ 8.4 - 8.2 (m, 2H), 8.1 - 8.0 (m, 2H), 5.0 - 5.1 (m, 4H), 2.1 - 1.9 (m,
4H), 1.5 - 1.2 (m, 8H), 0.84 (t, J = 6.8 Hz, 3H); 13C NMR (125 MHz, DMSO) δ
173.1 (2C), 136.8 (2C), 136.1 (2C), 132.7 (2C) 128.3, 128.1, 54.2, 54.1, 30.9,
28.7, 28.5, 25.4, 25.2, 22.3, 14.3; ESI/APCI calcd for C14H14N3O4+ ([M]++) m/z
325.1784; measured m/z 325.1773.
1,1'-(hexane-1,6-diyl)bis(3-octyl-4,9-dioxo-4,9-dihydro-1Hnaphtho[2,3-d][1,2,3]triazol-3-ium) triflate (NQ123C8). This compound was
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synthesized according to the general procedures with 84 % yield. 1H NMR (300
MHz, DMSO) δ 8.3 - 8.2 (m, 2H), 8.1 - 8.0 (m, 2H), 5.0 - 5.1 (m, 4H), 2.1 - 1.9 (m,
4H), 1.5 - 1.1 (m, 12H), 0.81 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, DMSO) δ
173.1 (2C), 136.9, 136.8, 136.1 (2C), 132.7 (2C), 128.3, 128.2, 54.2, 54.1, 31.6,
28.9, 28.8, 28.7, 28.5, 25.8, 25.1, 22.5, 14.4; ESI/APCI calcd for C42H54N6O4++
([M]++) m/z 353.2098; measured m/z 353.2083.
1,1'-(hexane-1,6-diyl)bis(3-decyl-4,9-dioxo-4,9-dihydro-1Hnaphtho[2,3-d][1,2,3]triazol-3-ium triflate (NQM123C10). This compound was
synthesized according to the general procedures with 84 % yield. 1H NMR (500
MHz, DMSO) δ 13C NMR (125 MHz, DMSO) δ 173.1 (2C), 136.8 (2C), 136.1
(2C), 132.7 (2C), 128.3 (2C), 128.1, 54.2, 54.1, 31.7, 39.4, 29.4, 29.1, 28.7(2C),
28.5, 25.8, 25.1, 22.6, 14.4.; ESI/APCI calcd for C46H62N6O4++ ([M]++) m/z
381.2411; measured m/z 381.2395.
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